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DISTINCT T CELL CLONES ARE ASSOCIATED WITH GRAFT-VERSUS-HOST DISEASE 
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     In patients undergoing hematopoietic stem cell transplantation (HSCT) with HLA-identical donors, 
genetic polymorphisms result in a mismatch between donors and recipients in their minor 
histocompatibility antigens (mHAgs), and tumors may also express tumor-associated antigens (TAA) 
that may not be abundantly present in the donors.  Donor T cells can recognize such mHAgs and TAAs 
as foreign antigens and generate an objective response against hematologic malignancies in a graft-
versus-tumor (GVT) effect.  However, a major side effect of HSCT occurs when donor T cells are 
alloreactive against the recipients’ normal cells, leading to graft-versus-host disease (GVHD).  The 
ability to identify T cell clones that are exclusively involved in the GVT or GVHD responses remains 
elusive.  In this study, we looked at clonally-driven CD3
+
 T cells in patients with hematologic 
malignancies prior to and after transplantation.  We identified V families of increased expression 
 ix 
 
involved in GVHD or GVT responses, with Vs 4, 11, and 23 being associated with GVHD, Vs 9, 16, 
and 20 being associated with GVT, and Vs 2, 3, 7, 8, 12, 15, and 17 being involved in GVHD and/or 
GVT.   We were also able to identify some of the V families that were increased in the peripheral 
blood at the site of GVHD.  Furthermore, one of our twelve patients had donor lymphocyte infusions 
(DLIs) for treatment of relapse, from which we were able to observe oligoclonal T cells that emerged at 
the time of post-DLI remission and re-establishment of GVHD.     
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Introduction 
 
 
 Hematologic cancers 
     It was estimated that over 1.5 million people were diagnosed with cancer in 2010, and that over 
500,000 died from their disease.
1
  Of these diagnoses, over 43,000 were with leukemia, roughly 74,000 
with lymphoma, and about 20,000 with myeloma.
1
  Leukemia, lymphoma, and myeloma are all blood 
cancers that derive from hematopoietic stem cells (HSCs).  Leukemias are defined by their cell 
precursors—either lymphoid or myeloid.  Lymphomas are derived from lymphocytes, and can be further 
classified as Hodgkin’s or Non-Hodgkin’s Lymphoma.  Myelomas are derived from plasma cells.  
Regardless of which cell types these cancers arise from, they are each a result of a dysregulation and 
malignant state of the hematopoietic system.  The treatment of many blood cancers requires high doses 
of chemotherapy and/or radiation treatments that destroy not only cancer cells, but also the patient’s 
healthy bone marrow.   
 Hematopoietic stem cell transplantation 
     Hematopoietic stem cell transplantation (HSCT) involves intravenous infusion of hematopoietic stem 
and progenitor cells to restore normal hematopoiesis and/or treat blood malignancies.  The clinical 
application of HSCT originated in the clinical observations of severe myelosuppressive effects from 
radiation among nuclear bomb survivors at Nagasaki and Hiroshima.
2
  In the 1950s and 1960s, research 
efforts were made to develop means of reversing myelosuppressive effects, including the infusion of 
bone marrow.  Subsequent determination and understanding of the major histocompatibility complex 
(MHC) and human leukocyte antigens (HLA) as the major determinant of graft rejection helped to 
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advance the clinical application of HSCT.
2
  Since the first successful transplantations in the 1960s and 
1970s, HSCT is now a standard treatment, and is performed in patients with various malignant and non-
malignant disorders in order to restore lymphohematopoiesis, replace diseased marrow, and reconstitute 
lymphohematopoiesis after marrow-ablative conditioning regimens.
2,3
    
     Prior to transplantation, patients undergo preparative regimens that are either myeloablative or non-
myeloablative.  The three major purposes of myeloablative conditioning regimens are to:  eradicate 
malignant disease, suppress the recipient’s immune system (to decrease the chance for graft rejection), 
and create space in the bone marrow microenvironment to allow engraftment of the donor stem cells.
3
  
The donor HSCs, also referred to as the graft, may be autologous (from the patient him- or herself), 
syngeneic (from an identical twin), or allogeneic (from any person other than the patient or an identical 
twin.
2 
     The success of HSCT in treating hematological malignancies is continually limited by acute 
complications such as infectious conditions, veno-occlusive disease of the liver, and acute and chronic 
graft-versus-host disease (GVHD).
3
  Due to preparative regimens with chemotherapy and/or radiation 
before HSCT, recipients suffer deficiencies in their cellular and humoral aspects of their immune system 
for a variable duration.
3
  The cellular immunodeficiency involves decreased T cell response to 
alloantigens and mitogens, decreased helper CD4
+
 T cell function, and decreased activity to intradermal 
skin tests.  Due to the thymic involution in recipients, T cell function is dependent upon the peripheral 
expansion of the few donor T cells that are present in the graft.
3
  Humoral immunodeficiency consists of 
a decrease in IgG isotype switching and antigen-specific responses, resulting in an impaired production 
of antibodies to pathogens.
3
  Recovery of the immune system occurs within the first six months to year 
after HSCT.  However, immunodeficiency is prolonged and more profound in patients with GVHD who 
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are under immunosuppressive therapy, and recovery of the immune system for these patients occurs 
after the discontinuation of their GVHD therapies.
3
   
  Graft-versus-host disease 
     Graft-versus-host disease develops when immunocompetent donor T cells are alloreactive against 
recipient tissues and organs.
4,5
  In 1966, Billingham outlined three general criteria for GVHD:  1) the 
donor cells must be immunologically competent; 2) the recipient must be immunocompromised, or 
incapable of rejecting the graft; and, 3) the recipient must express tissue antigens that are not present in 
the donor, such that they may be recognized as non-self.
4-6
  The genetic basis for the third criterion, that 
GVHD is a result of donor cells recognizing host antigens as non-self, is derived from genetic 
polymorphisms of the HLA and non-HLA systems (minor histocompatibility antigens (mHAgs), killer 
cell immunoglobulin-like receptors (KIRs), cytokines, and NOD2 genes).
7,8
  As a result of alloreactive T 
cells recognizing these genetic incompatibilities, there is poorer overall survival (OS) in those 
individuals who develop GVHD.
9
  
     Risk factors for GVHD include:  donor-recipient match at MHC loci (mismatches in HLA class I 
HLA-A, -B, -C or class II HLA-DRB1), donor stem cell source (bone marrow (BM) or peripheral blood 
stem cells (PBSC)), T cell dose, and other factors including donor and recipient age, donor-recipient sex 
mismatch (male recipient of female graft), donor parity and allosensitization, disease stage, and intensity 
of conditioning.
10
  General associations have been made with certain allele-level mismatches in the HLA 
genes, with mismatching of class I alleles being associated with increased risk of GVHD or graft 
rejection, whereas mismatching of the class II alleles has been associated with increased incidence of 
GVHD with no impact on graft rejection.
9,10 
     Today, GVHD is broadly categorized as chronic or acute.  Historically, GVHD was classified as 
chronic if it presented after 100 days post-HSCT, regardless if it was clinically indistinguishable from 
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acute GVHD (aGVHD).
11
  This classification was not satisfactory because acute and chronic GVHD 
have distinct clinical features that may sometimes present concomitantly and/or independent of the 
actual duration after transplant.  The NIH consensus now includes classification of GVHD as late-onset 
aGVHD (after day 100) and an overlap syndrome that has features of both acute and chronic GVHD.
8,11 
 Acute GHVD 
     Acute GVHD is graded (I-IV) based on the extent and severity of the involvement of the three major 
affected organs—the skin, liver, and gastrointestinal (GI) tract.3  Grades II to IV occur in roughly 20-
50% of patients who receive stem cell grafts from an HLA-matched sibling and in approximately 50-
80% of patients who receive grafts from an HLA-mismatched sibling or an HLA-matched unrelated 
donor (MUD).
3
  Long-term survival of patients with aGVHD is roughly 50% for those with grades 0-I 
and is as low as 11% for those with grade IV.
10
  Acute GVHD is characterized by dermatitis, hepatitis, 
and enteritis.  The onset of aGVHD is usually marked by a maculopapular rash involving the face, trunk, 
extremities, palms, soles, and ears.
10
   
     There is a general three phase model of the development of aGVHD:  1) activation of antigen-
presenting cells (APCs); 2) donor T cell activation, proliferation, differentiation, and migration; and 3) 
destruction of target tissue.
4,5,7,8
  The immune response is primed during phase one, in which APCs are 
activated by underlying disease and conditioning regimens.
7,8,12
  Conditioning regimens cause tissue 
damage, resulting in the production of ―danger signals,‖ including pro-inflammatory cytokines and 
chemokines, microbial products (i.e. – LPS, CpG) that enter systemic circulation from damaged 
intestinal mucosa, and necrotic cells.
4,5,8,13,14
  The inflammatory response promotes the activation and 
maturation of APCs, in which there is an increased expression of MHC, adhesion, and costimulatory 
molecules on host APCs, leading to an enhanced ability of donor T cells to recognize alloantigens, and 
subsequently become activated and proliferate.
8,15
  Phase two represents the core of the GVHD reaction 
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in which donor T cells are activated in response to host APC.  T cell activation is induced when T cell 
receptors (TCRs) recognize peptide:MHC complexes on APCs, and further requires a second signal 
which is generated by ligation of costimulatory molecules on APCs with their cognate receptors on T 
cells.
7
  These activated alloreactive T cells expand and differentiate into Th1/Tc1 or Th2/Tc2 cells, each 
of which has been associated with differences in the manifestation of GVHD,
7
 though Th1- and Tc1-
type cytokines (IL-1, IL-6, and TNF-produced by macrophages and monocytes;IFN- and IL-2 
produced by CD4 Th1 and CD8 Tc1 cells) are predominantly associated with development of aGVHD.
16
  
Once activated, these T cells migrate to target tissues and subsequently recruit other effector leukocytes.  
The homing of these T cells is regulated by adhesion, addressin, and chemokine receptor molecules in 
response to the production of chemokines in the injured target tissue, which is initiated by the 
conditioning regimen and is later amplified by the disease process.
7
  The effector, and third phase, is a 
complex cascade of both cellular mediators (such as cytotoxic T lymphocytes (CTLs) and natural killer 
(NK) cells) and soluble inflammatory mediators (such as TNF-α, IFN-γ, IL-1, and NO) that cause 
destruction of target tissue.
8,15
  With regards to cellular effectors, CTLs that preferentially use the 
Fas/FasL pathway of target lysis appear to predominate in GVHD damage of the liver (as hepatocytes 
express large amounts of Fas), whereas CTLs that use the perforin/granzyme pathways are more 
important in GVHD of the GI tract and skin.
8
  This effector stage of GVHD is perpetuated by the 
increased inflammatory signaling that is caused by tissue damage.
7
  Inflammatory effectors may be 
secreted as a result of stimulation of toll-like receptors (TLRs) by microbial products (such as LPS) that 
leak through intestinal mucosa or skin that is damaged from conditioning regimens.
4,8
  For this reason, it 
is thought that Peyer’s patches in the gut are initial sites of donor T cell activation by host APCs.7,8   
Chronic GVHD 
     Chronic GVHD can occur in up to 60% of patients who survive beyond 100 days after allogeneic 
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HSCT, and is a complication that develops more frequently 3 to 6 months after engraftment.
10,17,18
  In 
roughly 20% of patients with cGVHD, there is no evidence of previous aGVHD, suggesting that the two 
disease types have different pathogenesis.  Chronic GVHD is clinically manifested in a manner similar 
to that of autoimmune disorders, particularly scleroderma,
3
 and in contrast to aGVHD, is often 
characterized by fibrosis of the affected tissue or organ.
8
  There are a multitude of manifestations of 
cGVHD, including:  sicca syndrome (drying of the mouth and eyes), skin lesions (hypo- or 
hyperpigmentation, decreased elasticity, and loss of hair follicles and sweat glands), oral mucositis, 
esophageal strictures, kerato-conjunctivitis, malabsorption, hepatic involvement with 
hyperbilirubinemia, and suppressed hematopoietic reconstitution.
3
  Ten to twenty percent of patients 
with cGVHD develop bronchiolitis obliterans, which is associated with hypogammaglobulinemia and 
poor outcome.
3
 
     Like aGVHD, cGVHD is also thought to be induced by donor T cells, but the nature of relevant 
antigens and T cell subsets, as well as the mechanisms of cGVHD, are less well understood.
3,8
  There is 
an absence of appropriate experimental models that mimic all of the features of cGVHD, and this might 
be due to differences between the human and experimental species.
8,17
  Current animal models for 
cGVHD are difficult to relate to patient outcomes since chronic models more closely mimic non-
myeloablative transplants than full ablative allogeneic transplants, thus making the pathophysiology of 
cGVHD still poorly defined.
17
  Another difference is that, in contrast to murine studies, the kinetics of 
clinical cGVHD is slower and only observed after prophylaxis and/or treatment for aGVHD.  Even if 
clinical cGVHD arises de novo and in the absence of active immunosuppression (ISP), it is not possible 
to definitively rule out the impact of either GVHD prophylaxis and/or subclinical aGVHD on the 
subsequent development of cGVHD.
8
  Some experimental models have shown that T cells from animals 
with cGVHD are specific for a common (shared between donor and host) determinant of MHC class II 
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molecules and are consequently considered ―autoreactive.‖8  Such autoreactive T cells are associated 
with a damaged thymus and the inability to delete autoreactive clones.
17
  It has also been shown that 
autoreactive T cells can interact with IFNγ to produce the increased collagen deposition seen in chronic 
GVHD of the skin.
17
  Many experimental models of cGVHD have been characterized by Th2-type 
responses involving upregulation of Th2 cytokines (IL-4, IL-5, IL-10, TGF-) and antibody-mediated 
damage.
7,15-17
  The association of antibodies with cGVHD is also supported by the clinical observation 
in female to male HSCT in which antibodies specific to Y chromosome-encoded mHAgs are present.
8
  
Aside from the clinical correlation of antibodies with cGVHD, both Th1 and Th2 responses have been 
implicated in humans post-HSCT.
8,19
  
     Despite experimental evidence and clinical resemblance to autoimmune diseases, there is a lack of 
clear clinical data on the isolation of donor-derived T cell clones that recognize non-polymorphic 
antigens from both the recipients and donors.
8
  Instead, emerging clinical data show a strong correlation 
between the presence of immune responses against ubiquitously expressed mHAgs and cGVHD.
8,20
  
Acute GVHD is recognized more as a generalized state of donor-derived inflammation, in which tissue 
damage is mediated by activated donor effector cells and inflammatory cytokines.
16
  On the other hand, 
cGVHD is more representative of chronic antigen-stimulated specific cellular and humoral immune 
responses directed against specific epithelial tissues and hematopoietic cells.
8,16
 
     Current prophylaxis of GVHD includes immunosuppressive therapies (i.e.- cyclosporine, 
methotrexate) that have led to reductions in the incidences of GVHD, yet these therapies suppress T cell 
responses not only involved in GVHD, but also the immune system as a whole.
3
  Other preventative 
methods have attempted to reduce the incidence of GVHD by depleting T cells from the graft (TCD), 
but these treatments also led to increased risk of graft rejection, opportunistic infection, and relapse 
secondary to decreased graft-versus-tumor (GVT) effect.
3,21
  Established GVHD is predominantly 
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treated with high-dose corticosteroid treatments (i.e. - methylprednisolone), though this treatment fails 
for some patients who then must undergo salvage therapy.  Second line treatments include 
extracorporeal photophoresis (ECP), anti-thymocyte globulin (ATG), cytokine blockades (i.e. – TNFα 
antibodies), anti-CD3 antibodies, and chemotherapeutic agents (i.e. – nucleoside analogs), among 
others.
3,10,22,23
  These current broad spectrum treatments are not ideal because they render patients 
susceptible to relapse and infectious complications. 
Graft-versus-tumor effect 
     Beyond restoring lymphohematopoiesis, it was eventually found that donor cells were capable of 
providing an immunological response against malignant and diseased recipient cells, independent of 
chemotherapy and radiation treatments.  In 1956, Barnes et al. demonstrated that irradiated mice that 
received allogeneic marrow transplants, but not syngeneic transplants, showed remission of leukemia.
24
  
This murine experiment was the first to suggest that donor cells may provide a graft-versus-leukemia 
(GVL) or graft-versus-tumor (GVT) effect.  The implications of this murine experiment were realized in 
human studies showing that relapse rates in patients were decreased in those who developed some form 
of GVHD, suggesting that alloreactive donor cells were involved not only in GVHD but also in a GVT 
effect.
9
  It is because of experimental and clinical validations of the importance of donor alloreactivity 
that HSCT is becoming more of an immunotherapy, as opposed to an initial means of delivering high 
dose therapies and replacing damaged hematopoietic cells with normal stem cells.
9,21
 
     It has also been shown that relapse rates are higher in patients who receive TCD grafts or who 
receive grafts from identical twins (syngeneic),
25
 suggesting the role for T cells in alloreactivity of GVT 
responses.  The significant role of immunocompetent donor cells has been further shown in patients who 
received donor lymphocyte infusions (DLI) post-transplant to treat recurrence of disease.
25-27
  Many 
experimental and human models focus on CTLs and NK cells, with CD8
+
 T cells being the predominant 
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T cell subset implicated in the GVT effect.
28-33
  The dominance of one subset over another likely varies 
with degree of genetic disparities between donors and recipients, both with regards to HLA and 
mHAgs.
34
  Furthermore, there are three general ideas as to how GVT effects are mediated:  1) through 
direct killing of malignant cells by perforin- and granzyme-mediated attack from CTLs (CD8
+ 
and CD4
+
 
T cells, and NK cells); 2) by apoptotic cell death via the Fas/FasL pathway (CD8
+
 and CD4
+
 T cells); or 
3) by cytokine-mediated malignant cell death (CTLs) or control of proliferation (predominantly CD4
+
 T 
cells) [reviewed in Barrett, 1997].
34
  Aside from helper roles in augmenting CD8
+
 CTL responses, CD4
+
 
T cells have also been associated with cytotoxic function in a class II-restricted fashion.
29,34-37
 
     Just as in GVHD, mHAgs are key players in the GVT effect in HLA-matched allogeneic HSCT.  
There has been an association of cGVHD with lower relapse rates, but it isn’t known if the GVT effect 
relies on cGVHD or if it independently persists once cGVHD is resolved.
17, 25
  There are two general 
types of antigens that may be targeted in a GVT capacity – polymorphic mHAgs or autologous antigens 
that are specifically associated with a malignant phenotype (tumor-associated antigens, or, TAAs).
9,28,38
   
Minor histocompatibility antigens 
     Minor histocompatibility antigens are peptide epitopes that are derived from the degradation of 
normal cellular proteins, and are presented on either MHC class I or class II molecules.
15 
mHAgs are a 
result of genetic variation, though the means of this variation is diverse.   Genomic variations may occur 
via gene deletions, inverted gene sequences, multiple copy gene duplications, segmental duplications, 
large-scale copy number variations (CNVs) and single nucleotide polymorphisms (SNPs).
15
  
Nonsynonymous coding SNPs and deletion polymorphisms are crucial players in the generation of 
potentially immunogenic transplantation antigens as they have been identified most in autosomal 
mHAgs, and SNPs cause differences in the amino acid sequences of homologous proteins between 
recipient and donors cells.  A single amino acid substitution can cause altered proteosomal cleavage, 
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peptide transport, HLA binding or TCR contact, all of which may trigger donor T cells to recognize 
these peptides as non-self.
15
  
     Some of the most common mHAgs studied with regards to HSCT are from genes on the Y 
chromosome, which have shown polymorphisms with the homologous regions of the X chromosome.  In 
the HSCT setting, this is relevant in sex-mismatched transplants in which male patients are recipients of 
female stem cell grafts.  It has been shown that male recipients of female grafts have a higher risk of 
developing GVHD and a lower risk of relapse, suggesting that some mHAgs encoded on the Y 
chromosome may be immunodominant.
15,29,39
  HA-Y mHAgs are ubiquitously expressed,
40,41
 and some 
of the mHAgs encoded on the Y chromosome include UTY, SMCY, and DBY.
42
  SMCY and DBY are 
highly expressed on epithelial cells, suggesting a role for T-cell-mediated responses against these 
mHAgs in either GVHD or GVT effects.
42
  UTY is only moderately expressed on epithelial cells, 
suggesting that UTY-specific T cells may promote GVT effects without augmenting GVHD.
42
   
     Other mHAgs that are commonly studied are HA-1, -2, and -3.  HA-1 and HA-2 are preferentially 
expressed on hematopoietic tissues, therefore allowing them to be targeted by HA-1 and HA-2-specific 
T cells in a GVT effect without augmenting GVHD (though HA-1 expression has also been implicated 
in solid tumors).
16,20,32,38
  HA-3 is preferentially expressed on non-hematopoietic tissues, suggesting it 
may be a target of GVHD more so than GVT effects.
42
  Overall with regards to mHAgs, those that are 
ubiquitously expressed are prime targets for GVHD, whereas those that are restricted to the 
hematopoietic system may fulfill their role in eliciting a GVT response without increasing the risks of 
GVHD.
16,32,43
    However, it has also been shown that hematopoietic cells at the site of GVHD may have 
a role in the development of low grade GVHD, even though the mHAgs themselves are not ubiquitously 
expressed on the actual tissues involved in GVHD.
20 
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The HLA System 
     The immunological reactions that are involved in the transplantation process—GVHD and GVT 
effects—develop primarily from the HLA system, which is essential in T cell activation through the 
HLA presentation of peptides to T cells.
9
  The HLA genes are located within the MHC on the short arm 
of chromosome 6, and includes over 200 genes.
44
  The HLA class I genes code for the α polypeptide 
chain of the class I molecule, whereas the β chain is encoded by the β2-microglobulin gene on 
chromosome 15.  There are five domains in the α chain:  two peptide-binding (α1 and α2), one 
immunoglobulin-like (α3), a transmembrane region, and a cytoplasmic tail.  Of 20 HLA class I genes, 
three are the major components of the immune system:  HLA –A, –B, and –C.44  Unlike class I, the class 
II genes for both the α and β polypeptide chains are located on chromosome 6.  The class II genes are 
designated by three letters:  the first represents the class (D), the second represents the family (M, O, P, 
Q, or R), and the third represents the chain (A or B, which corresponds to α or β, respectively).  There 
are four domains in each of the α and β chains:  peptide-binding (α1 or β1), immunoglobulin-like (α2 or 
β2), the transmembrane region, and the cytoplasmic tail.44  These two classes contain the major 
influential genes that are matched between donor and recipient in HSCT—HLA-A, -B, and –C genes 
from class I, and HLA-DRB1, -DQB1, and –DPB1 genes from class II.9 
    Class I genes are expressed on most all nucleated cells, though their level of expression is tissue-
dependent.
9,44
  Class II gene expression is restricted to hematopoietic cells, and are expressed 
predominantly on immune cells (APCs—including B cells, dendritic cells, and macrophages; and also 
thymic epithelial cells).
25,44
  Furthermore, the expression of class II HLA molecules can be induced 
during inflammatory responses, such as in the presence of IFN-γ.9,44  Class I molecules are recognized 
by CD8
+
 T cells, and class II molecules are recognized by CD4
+
 T cells.
8,9
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     Class I and class II molecules present peptides to the TCR, and hence are involved in the activation 
of T cells associated with both GVHD and GVT effects.  Traditionally, class I molecules present 
endogenous proteins, whereas class II molecules present exogenous proteins, though these designations 
are not absolute.
45
  Class I molecules may present exogenous proteins, such as bacterial proteins, and 
class II molecules may present endogenously produced proteins such as viral proteins, though the 
mechanisms of these exceptions to the general rule are not well understood.
44
 
     Endogenous proteins are primarily marked by ubiquitin for degradation in the proteosomes, though 
some proteins may be degraded by soluble enzymes in the cytosol.  The degraded peptides are either 
further degraded into amino acids in the cytosol or are transferred to the endoplasmic reticulum (ER).  
Of endogenously degraded peptides, some are picked up with transporters associated with antigen 
processing (TAPs), which are encoded by TAP1 and TAP2 genes.  TAP1 and TAP2 proteins form a 
channel on the endoplasmic reticulum that allows peptides to enter the endoplasmic reticulum, the 
luminal side of which has class I molecules.  Once a suitable peptide is bound to the class I molecule, 
the peptide-bound HLA molecule then moves to the plasma membrane and presents itself to other 
cells.
44
   
     The processing of and peptide-loading of exogenous proteins on class II molecules is primarily 
restricted to B cells, dendritic cells, and macrophages. Exogenous proteins are endocytosed into vesicles 
that fuse with primary lysosomes which then acquire proteolytic enzymes and form endosomes in which 
the proteins are degraded.
44
  Though they are also assembled on the luminal surface of the endoplasmic 
reticulum, unlike class I molecules, class II molecules do not bind with peptides in the ER, but rather 
with a protein that prevents premature binding of peptide—the invariant chain.  Class II molecule-
invariant chain complexes enclosed in membranous vesicles meet their exogenous proteins upon 
interaction with endosomes in the cytosol.
44
  These two vesicles fuse to form the MHC class II 
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compartment, in which exogenous proteins and most of the invariant chain are degraded by proteases. 
To separate the part of the invariant chain that is bound to the class II molecule, other class II molecules 
(HLA-DM) dislodge the remaining part and free the peptide-binding groove.  Once a peptide binds to 
the class II molecule, these complexes are then transported to the surface of the cell.
44
  Cell surfaces 
become decorated with as many as 100,000 to 300,000 of each of the class I and class II MHC-peptide 
bound complexes.  As such, each normal, or uninfected, cell displays self peptides on the order of 
hundreds or thousands on its surface.  Most peptides are displayed with around 100 copies, whereas 
others may present only a few or thousands of copies.
44
   
     During T cell development and maturation in the thymus, the immune system develops a tolerance to 
―self‖ proteins and thus has the ability to distinguish between ―self‖ and ―non-self‖ proteins and peptides 
that are displayed in the context of MHC.  In HSCT, it is from the recognition of ―non-self‖ proteins 
that:  grafts may be rejected by host cells reacting against donor cells, alloreactive donor cells may target 
normal tissues of the host, causing GVHD, and/or donor cells may react against host antigens that are 
associated with malignancy and disease, conferring a GVT effect.
9
  Even with a ―perfect‖ HLA match, 
due to extensive polymorphism, an immense number of non-HLA antigens, primarily mHAgs, may be 
presented to T cells, and subsequently induce alloreactivity involved in either GVHD or GVT effects.   
 T cell Development  
     Pluripotent hematopoietic stem cells in the bone marrow give rise to common lymphoid and myeloid 
progenitors.  It is the common lymphoid progenitors that, after leaving the bone marrow, enter the 
thymus and give rise to thymocytes.  In the thymus, differentiation of immature thymocytes is mediated 
by the integration of intrinsic signals, which are generated downstream of the TCR, and extrinsic 
signals, which are obtained from numerous interactions of T cell progenitors with stromal cells and other 
thymocytes.
46
  T cell development in the thymus can be separated into three broad steps:  the first 
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spanning thymic colonization to T cell commitment; the second proceeding to the divergence of αβ and 
γδ lineages; and, the third consisting of αβ and γδ lineage cells completing their differentiation and 
acquiring immunological properties.
47
   
     The two distinct T cell lineages—αβ and γδ—arise from common precursor cells termed double-
negative (DN) thymocytes (because they lack expression of CD4 and CD8 co-receptors).
46
  DN cells are 
further divided into subsets based on their developmental potential (DN1(a-e), DN2, and DN3(a,b)).  
Transition from the DN1 to DN2 stage marks the initiation of gene rearrangement at the TCRβ, TCRγ, 
and TCRδ gene loci.  Successful rearrangement of the Tcrd and Tcrg genes promotes the assembly of γδ 
TCRs.  The αβ TCR is preceded by a pre-TCR that is formed when successful recombination of the Tcrb 
gene promotes the assembly of a TCRβ-chain, which then pairs with a surrogate TCRα-chain (the 
invariant pre-Tα protein).46  The expression of a functional pre-TCR represents the controlled 
developmental transition beyond the DN3 stage, and is referred to as the β-selection checkpoint.46  The 
β-selection checkpoint is crucial in identifying proper TCR gene rearrangement at the DN3 stage 
because nucleotide deletions and additions may be introduced during RAG-mediated recombination, 
with most of the rearrangements being out-of-frame and incapable of producing functional protein.
47
  
During the DN3 stage, those cells which express either a pre-TCR or a γδ TCR are rescued from 
apoptosis and subsequently undergo thymocyte proliferation and differentiation.
46,48
  Along with these 
β-selection and γδ-selection events, CD5 and CD27 are upregulated and the cells increase in size, 
marking the transition from pre-selection DN3a to post-selection DN3b.  Next, the αβ T cell lineages 
downregulate CD25 and upregulate CD4 and CD8, thus becoming characterized as double-positive (DP) 
CD4
+
CD8
+
 cells.
46
  In contrast to the αβ T cell lineage, most of the γδ lineage remain DN.46 At this stage 
in DP αβ T cells, Rag genes are re-expressed, initiating TCRα gene rearrangement and promoting the 
assembly of the αβ TCR heterodimers.46,48  DP thymocytes are programmed to undergo apoptosis unless 
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they receive a ―rescue signal‖ (positive selection) through the ability of their TCR to bind an MHC 
ligand with mild avidity.
49
  During a three day window before programmed cell death, receptor editing 
occurs in which sequential rounds of rearrangement of the TCR-α locus occurs, increasing the chance of 
successful self-MHC restriction.  For DP thymocytes whose TCR interacts poorly with self-
peptide:MHC ligands and are subsequently unable to generate intracellular signaling needed to sustain 
viability, they undergo ―death by neglect.‖50  Some thymocytes bind to self-peptide:MHC with high 
avidity and as a result, apoptosis is promoted to prevent an autoimmune pathology that would result if 
these cells were to exit the thymus and enter the periphery.
50
  This strong interaction is referred to as 
―negative selection,‖ or clonal deletion.  In the end, approximately 95% of DP cells fail positive 
selection and undergo ―death by neglect.‖  For the roughly 5% of DP cells that are positively selected, 
DP maturation to the single-positive (SP) stage (CD4
+
CD8
-
 or CD4
-
CD8
+
) is induced.
49
 
     The alloreactivity that characterizes both GVHD and GVT effects represents the cross-reactivity of 
TCRs for non-self peptide:non-self MHC complexes. This interaction is influenced by both the bound 
peptide and the MHC molecule, and may be categorized into three types:  peptide:MHC dependent in 
which alloreactive T cells interact strongly with one specific peptide:MHC complex, but not with the 
same MHC bound to different peptides; peptide-dependent in which the peptides presented by non-self 
MHC differ from the peptides of the host; and peptide-independent in which alloreactive T cells 
recognize non-self MHC without a strict peptide requirement.
51
  Because the majority of our patients 
received stem cell grafts from matched HLA-donors, we are primarily interested in the peptide-
dependent reactivity of TCRs.   
 TCR rearrangement and the CDR3 region 
     The somatic assembly of the TCR genes generates a diverse T cell repertoire during thymocyte 
development.  The four TCR genes—Tcra, Tcrb, Tcrg, Tcrd—are assembled through V(D)J 
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recombination, which is a site-specific recombination process that is directed by the lymphoid-specific 
recombinase (RAG, comprised of RAG1 and RAG2) and the ubiquitously expressed DNA repair 
proteins.
48
  The RAG proteins generate double-strand breaks at recombination signal sequences (RSSs) 
that flank the TCR variable (V), diversity (D) and joining (J) gene segments.  These breaks are 
subsequently resolved by non-homologous end joining.
48
  The alpha and gamma loci undergo 
recombination between the variable (V) and joining (J) segments.  The beta and delta loci undergo 
recombination between V and J segments, and further include one of two short diversity (D) segments.
52
  
There are 52 functional Vβ, 2 Dβ and 13 Jβ segments that undergo VDJ rearrangements to generate Vβ 
regions.
53
  The αβ T cells constitute the bulk of T cell populations in lymphoid organs and normally 
react to peptides that are presented in the context of MHC class I or class II molecules.
47
  In contrast, the 
γδ T cells are typically not MHC-restricted and seem to be involved in the surveillance of microbial and 
non-microbial tissue stress.  The specificity of clonally distributed αβ TCRs is diversified through the 
random rearrangement of V and J genes at the TCRα locus and V, D, and J genes at the TCRβ locus of 
developing thymic T cells.  Diversity is further created through random nucleotide insertion and deletion 
of a variable number of nucleotides at the VDJ junctional sites (N-regions).
53, 54
   
     Greater than 95% of T cells have αβ TCRs.55  The TCR’s recognition specificity for diverse 
peptide:MHC complexes is determined by its three complementarity-determining regions (CDRs):  
CDR-1, -2, and -3.  CDR1 and CDR2 are coded by germline sequences (Vα and Vβ genes), whereas 
CDR3 is derived from the V-(D)-J and N-regions made during somatic recombination.
52-53
  The TCR 
interaction with peptide:MHC complexes suggests a common diagonal docking mode, whereby the 
CDR1 and CDR2 loops contact the MHC α helices of the antigen binding groove and the more diverse 
CDR3 α and β loops interact primarily with the peptide.  The CDR3 is the highly polymorphic 
recognition site of the TCR that recognizes antigen specificity, and it is for the additional diversity 
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generated at the CDR3 recombination junctions that the CDR3 is capable of recognizing such a vast 
number of peptide:MHC complexes.
52 
     By analyzing the variable region of the TCR CDR3 region, we can determine the clonality of T cell 
responses, as different CDR3 sizes correspond to different T cell clones.
55
  Due to the imprecise nature 
of combinatorial diversity and the random addition of nucleotides, each T cell clones expresses a unique 
CDR3 region of the TCR V.56  Healthy individuals have highly diverse and polyclonal TCR repertoires 
that typically express 8 to 10 different sizes for each Vβ CDR3 region separated by 3 nucleotides.53  
Oligoclonal and monoclonal TCR repertoires are associated with strong immune responses.
52
  
Oligoclonal expansion of TCR Vβ families is common and often correlates with GVHD.53   
 Hypothesis/Aims 
     Because treatment of GVHD is dominated by broad immunosuppression that leaves patients at 
greater risk for complications from infections and abrogation of the GVT effect, there is still a need to 
develop a method to directly target GVHD-causing T cells while sparing those involved in host defense 
and immunosurveillance.
57
  As GVHD and GVT are both predominantly T-cell-mediated processes, 
analysis of patients’ T cell repertoires may elucidate T cell populations involved in the pathogenesis of 
these processes.  In a cohort of twelve patients who have undergone allogeneic HSCT for various 
hematologic malignancies, we performed quantitative RT-PCR (qRT-PCR) and CDR3 spectratyping of 
peripheral T cells to identify antigen-driven T cell responses associated with GVHD and/or GVT effects.  
Furthermore, by extracting DNA from GVHD biopsy samples, we are able to not only detect T cell 
clones at the site of GVHD, but also correlate those at the site of disease with those identified in the 
peripheral blood.   
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Materials and Methods 
 
 
Patients 
     Twelve patients with hematological malignancies (4 with Non-Hodgkin’s Lymphoma, 5 with 
multiple myeloma,  2 with chronic lymphocytic leukemia, and 1 with prolymphocytic leukemia) who 
underwent allogeneic hematopoietic stem cell transplantation (HSCT) were included in this study.  
Table 1 outlines patient characteristics and Figure 1 depicts the treatment schedule.  Also included in the 
study was data from the patients’ respective donors in order to compare the T cell repertoire of the 
patients relative to their donors at various time points post-HSCT.  Donor peripheral blood CD34
+
 stem 
cells (D) were collected at the time of transplant, from which we collected samples, and peripheral blood 
samples from recipients were collected prior to and at various time points after transplantation:  R 
(recipient) denotes pre-transplant before the start of the conditioning regimen; R2 denotes 3 months after 
HSCT for all patients, except for Patients 5, 11, 13, and 14, in which R2 denotes time of GVHD onset; 
R3 denotes one year post-transplantation for the four patients without GVHD (Patients 3, 4, 7, and 12) 
and either the time of GVHD onset (Patients 6, 8, 9, 10) or 3 months post-transplantation (Patients 11, 
13, and 14) for the patients who developed GVHD; R4 denotes one year post-transplantation in the 
GVHD group (Patients 6, 8, 9, and 11), times of active GVHD for Patients 13 (6 months post-transplant) 
and 14 (4 months post-transplant), and time of relapse for Patient 10 (10 months post-transplant); R5 
denotes one-year post-transplant for Patient 13 and Patient 10 (R5 is also post-DLI for Patient 10); 
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Patients 5 and 14 do not have one-year samples, as both expired prior to this time.  Patient 10 also has an 
R6 sample that is roughly 22 months post-HSCT and represents time of remission and re-establishment 
of GVHD post-DLI treatments that were roughly 2 and 11 months prior to R6.  Patient outcomes are 
outlined in Table 2, with regards to onset and treatment of GVHD. All patients were informed of the 
purpose for the study and agreed to participate.  This study was approved by the VCU Institutional 
Review Board for the collection of donor CD34
+
 stem cells and peripheral blood samples from patients 
undergoing HSCT at VCUHS, at the time points aforementioned.  
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Figure 1:  
 
 
 
 
 
 
 
 
 
Figure 1.  Treatment regimen for patients undergoing allogeneic HSCT.  The treatment regimen 
consisted of rabbit anti-thymocyte globulin (ATG) (doses between days -9 and -7) and 450 cGy total 
body irradiation in three fractions on days -1 and 0.  Patients were randomized as to which ATG dose 
they would receive.  GVHD prophylaxis with tacrolimus is denoted by the light blue taper (day -3 to 
120) and with mycophenolate mofetil (MMF) denoted by the dark blue bar (day 0-30).  MRD:  matched 
related donor; MUD:  matched unrelated donor. 
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Table 1.  Patient characteristics.  
 
 
 
 
 
 
MM: multiple myeloma; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; PLL: 
prolymphocytic leukemia; PR: partial response; CR: complete response; MRD: matched related donor; 
MUD: matched unrelated donor; HLA code translation for WTR: 01/06/18 
 
 22 
 
 
 
Table 2.  Patient outcomes following HSCT. 
 
 
Patients 
*T cell chimerism  Days post-
HSCT 
R2/R3/R4 
Patients’ 
outcome/day 
of GVHD  
post-HSCT 
Treatment for 
GVHD 
Days 
post-
HSCT 
death R2 R3 
3 11% 0 88/ 365/ NA 
No relapse/  
No GVHD 
NA   
4 51% 8% 90/ 322/ NA 
No relapse/  
No GVHD 
NA   
7 52% 63% 85/ 298/ NA 
No relapse/  
No GVHD 
NA   
12 9% 0% 94/ 356/ NA 
No relapse/  
No GVHD 
NA   
5 0 0 89/ NA/ NA 
No relapse 
GVHD/89 
Steroids/ ECP 162 
6 0 0 90/ 148/ 372 
No relapse  
GVHD/148 
Tac/steroids/ ECP   
8 2% 3% 79/ 123/ 363 
No relapse  
GVHD/123 
Tac/steroids 404 
9 2% 1% 81/ 120/ 362 
No relapse 
GVHD/120 
Tac/steroids   
10 0 0 102/ 172/ 291 
Relapse/291 
GVHD/160 
Steroid topical   
11 0 0 54/ 87/ 364 
No relapse 
GVHD/54 
Tac/steroids/rituxan   
13 0 0 65/ 96/ 141 
No relapse 
GVHD/65 
Steroid topical   
14 0 0 66/ 97/ 129 
No relapse 
GVHD/66 
Tac/steroids/rituxan 171 
 
 
Percentages indicate the proportion of T cells that are not from the engrafted donor T cells (recipient T 
cells).  ECP:  extracorporeal photophoresis; Tac:  tacrolimus.   
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Table 3.  Cell counts of donor stem cell grafts.   
 
Patient CD3 x 10^8/kg 
CD34 x 
10^6/kg 
3 3.54 6.52 
4 2.31 6.8 
7 5.54 6.81 
12 1.26 7.99 
5 5.68 2.05 
6 1.66 5.16 
8 3.72 7.45 
9 2.86 6.23 
10 3.53 3.43 
11 11.35 5.13 
13 0.43 1.9 
14 1.5 4.96 
 
CD3
+
 counts are 10^8/kg of recipient weight.  CD34
+
 counts are 10^6/kg recipient weight.  Patients 3,4, 
7, and 12 are GVHD-free and Patients 5, 6, 8-11, 13 and 14 developed GVHD.
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T cell isolation and mRNA Extraction 
 
     Recipient blood samples were taken at the time points described above (R-R5), diluted with a 1:1 
salt solution, and subsequently layered on Ficoll-Paque™ Premium (GE Healthcare) for density 
gradient centrifugation and isolation of mononuclear cells (according to manufacturer’s protocol).  
These cells, after washing, were cultured in RPMI medium containing 0.1% autologous serum for 2 
hours at 37°C and non-adherent cells were collected.  CD3
+
 cells were isolated using the EasySep® 
Negative Selection Human T cell Enrichment Kit (Stem Cell Technologies) according to 
manufacturer’s protocol.  Subsequently, isolated CD3+ T cells were used for RNA extraction using 
Trizol (Invitrogen).   For donors, RNA was extracted from peripheral blood CD34
+
 stem cells.  We 
determined that un-fractionated CD34
+
 stem cells still had a high yield of CD3
+
 T cells in comparison 
to CD3
+
 fractions isolated using a T cell enrichment kit (Figure 2).  Therefore, the T cell enrichment kit 
was only used for recipient samples, and we proceeded directly to culturing donor CD34
+
 stem cells in 
serum-free medium at 37
o
C for 2 hours and collected non-adherent cells.   
   
 
 
GAPDH
CD3ε
CD3+ fractionUnfractionated
CD34+ cells
 
 
Figure 2.  CD3+ fractions in un-fractionated CD34
+
 stem cells and in isolated CD3
+
 cells.  PCR 
products on a 1% agarose gel showing CD3
+
 cells in un-fractionated CD34
+
 cells and in T cells isolated 
using a negative selection T cell enrichment kit (CD3
+
 fraction).  GAPDH is shown as a control.   
 
Figure 2 
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     RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol.  
Next, DNase treatment was performed using RQ1 RNase-free DNase (Promega, according to 
manufacturer’s protocol) to digest DNA contamination.  Double-stranded cDNA was prepared from 1μg 
of total RNA using the SuperScript™ II reverse transcriptase (Invitrogen) with a dT18 oligonucleotide 
primer.  The cDNA synthesis was completed at 42°C for 2 hours. 
Quantitative RT-PCR 
     Using reverse primers for 23 functional TCR V58 families and one forward primer for the constant 
region of the TCR V(Table 4), qRT-PCR was performed for amplification of the CDR3 region using 
SensiMix™ SYBR & Fluorescein Kit (BIOLINE) and BioRad’s CFX96 Real-Time PCR Detection 
System.  Reaction mixtures of 20μl were prepared according to manufacturer’s protocol and 5μl of 30-
times diluted cDNA were used as a template.  Thermo-cycle conditions consisted of initial denaturation 
at 95°C (10 min. each), followed by 40 cycles at 95°C (15 s) and 60°C (1 min.).  The fluorescent data 
was acquired during each extension phase.  After 40 cycles, a melting curve was generated by slowly 
increasing the temperature from 60°C to 95°C, while the fluorescence was measured.  Amplification of 
CD3ε fragments with specific primers (forward 5'-CGTTCAGTTCCCTCCTTTTCTT-3', reverse-5'-
GATTAGGGGGTTGGTAGGGAGTG-3'),
59
 was used as a normalization control to quantify the 
relative expression of different TCR V families.  The expression of each V family in recipients was 
compared to that of their donors to demonstrate the change in the level of mRNA.  A constant donor 
sample was used as a control to be able to compare multiple experiments.   
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Statistical consideration 
     A 1-fold increase in expression of the recipients’ V over their donors’ V was used as an arbitrary 
cutoff used to distinguish meaningful increases in TCR V.  Since the CD3ε subunits were used for 
normalization and there are two CD3ε subunits and one CDR3 region associated with each TCR, the 
amount of CD3 template was twice as much as that of each TCR V template.  Therefore, a 1-fold 
increased expression of a given V over CD3 may indicate T cell activation. 
 Spectratyping analysis of the CDR3 region 
     PCR products were prepared using 5μl 30-times diluted cDNA and a 20μl PCR master mix 
containing 1X PCR Buffer, 1.5 mM MgCl2, 2.5 units of Velocity DNA Polymerase (Bioline), 1 μM V-
specific primer, and 1 μM of a FAM-tagged primer specific for the constant region of TCR (Table 4).  
PCR conditions were run as follows:  94C (5 min.), 94C (30s), 60C (30s), 72C (1 min.) for 35 cycles 
followed by 10 min. extension at 72C.   
     PCR products were analyzed at Roswell Park Cancer Institute using an ABI Prism 3130 capillary 
sequencer followed by fragment length analysis of the CDR3 region with GeneMapper® software.  
Spectratyping results were analyzed with PeakScanner™ Software v1.0 from Applied Biosystems. 
 27 
 
 
Table 4.  TCR V primers. 
 
 
 
 
 Degenerate bases:  M = A/C; Y = C/T; R = A/G; K = T/G. 
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DNA Extraction 
    Paraffin-embedded biopsy samples from the site of GVHD were available for Patients 5, 6, 8, and 
11.  DNA extraction methods were previously described by Fan and Gulley.
60
  From five 5µm thick 
sections, paraffin was dissolved using xylene washes.  Xylene was was removed with ethanol washes 
and ethanol was evaporated in a dry heat block at 55°C.  A Proteinase K solution (20mg/mL) in TEN 
buffer was added to the samples (100-150µL) and the samples were incubated at 55°C for at least 3 
hours.  To inactivate the Proteinase K, samples were incubated at 95°C for 10 minutes.  Tissues were 
pelleted in eppendorf tubes and the supernatant was removed for use as template in PCR reactions.  In 
order to check quality of DNA, PCR using primers specific for GAPDH (forward 5'-
ATTGCCCTCAACGACCACTTTG-3', reverse-5'-TTGATGGTACATGACAAGGTGCGG-3')
61
 was 
run.  PCR reactions were run for those V families in which both increased expression and 
oligoclonality were demonstrated in qRT-PCR and spectratyping, respectively.  The primers used are 
the same as those outlined in Table 3, without a FAM-tag on the primer for the constant region of the 
TCR.  PCR products were run on a 1% agarose gel to identify those V families that could be identified 
at the site of GVHD. 
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Results 
 
 
TCR V families 4, 11, and 23 are associated with GVHD. 
     Using qRT-PCR, we looked at the expression of 23 TCR V families in patients relative to that of 
their donors in order to identify changes in the T cell repertoire following allogeneic HSCT.   As shown 
in Figure 3, we identified TCR V families 4, 11, and 23 as those which demonstrated increased 
expression in multiple patients with GVHD (with the exception of increased expressions in Patient 12, 
who did not develop GVHD).  TCR V4 was increased in recipients, relative to their respective donors, 
at the time of GVHD in Patients 5, 6, 8, and 10.  TCR V11 was increased in Patients 5, 8, 9, 10 and 
13, and TCR V23 was increased in Patients 5, 9, 10, 11, and 13, all at their respective times of GVHD.  
In a few instances, an increased expression was also seen at the time point prior to the clinical 
manifestation of GVHD, suggesting that T cell clones involved in the pathophysiology of GVHD may 
be detectable in the blood prior to diagnosis of the disease.  This was seen in Patients 8 and 10 at R2 in 
V4, in Patients 8 and 9 at R2 in V11, and in Patient 9 at R2 in V23. 
     Increased expression of T cells is due to either antigen-specific responses or homeostatic 
proliferation.  In order to determine if TCR Vfamilies 4, 11 and 23 were antigen-driven, and 
potentially temporally associated with the incidence of GVHD, we performed spectratyping analysis of 
the CDR3 region.  Correspondingly, for V4, spectratyping analysis demonstrated oligoclonality in 
Patient 5 and monoclonality in Patients 6, 8, and 10 at their respective times of GVHD (Figure 4a).  
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Oligoclonality was also seen at R2 in Patients 8 and 10, as expected by their corresponding increases in 
qRT-PCR at both R2 and R3 (Figure 3, 4a), which suggests that clonotypes involved in GVHD may be 
detectable prior to clinical diagnosis.  Patient 6 demonstrated monoclonality at R2 when there was not 
an increased expression of V4, and this clone also mirrored that seen in the donor and at R4, 
suggesting that it may have been an antigen-experienced T cell population (Figures 3, 4a).  The clone 
seen at time of clinical diagnosis of GVHD (R3) was different from these other timepoints, suggesting 
that it may have emerged in a temporal fashion in association with the onset of GVHD (Figure 4a).  
Patient 6’s GVHD was still being treated at one year post-HSCT (R4), so it was expected that the same 
clonotype size would persist, though the clone at this time coincided with that seen in the donor as well 
as in the recipient prior to GVHD.  A possible explanation could be that the clonal population that 
emerged at R3 did coincide with onset of acute gut GVHD, but that the severity of the disease was 
greatly diminished at R4, such that the clonal population was no longer actively proliferating.  With 
regards to Patient 10, there was a continuation of clonality after the timepoint of GVHD (R4), and since 
GVHD was not wholly resolved at this time (10-months post-HSCT), the continuation of a GVHD-
associated clone was expected. 
     Spectratyping anaylsis of TCR V11 showed monoclonality at the time of GVHD in Patients 5, 8, 9, 
and 10 (Figure 4b).  (Due to sample limitations there is no spectratyping analysis of Patient 13.)  
Patients 8 and 9 also demonstrated increased expression and monoclonality at the timepoint prior to 
GVHD-onset (Figures 3, 4b), and since both patients were still on GVHD prophylactic 
immunosuppression at R2, the oligoclonality may be due to the emergence of the GVHD-specific 
clonotypes early-on during lymphopenia in which peripheral expansion is promoted in efforts to re-
establish the T cell repertoire.  This further suggests that the alloreactive clonotypes may be detected 
prior to clinical manifestation of GVHD, or they may represent restoration of a limited T cell 
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population.  For Patient 10, there was oligoclonality prior to GVHD (R2), which mirrored the donor’s 
repertoire and there was no increased expression of V11 at this time, so it may be representative of 
delayed thymopoiesis as the thymus may be damaged by conditioning regimens and its function is 
greatly reduced after the involution of the thymus during puberty.
62
  A different clonotype emerged at 
the time of GVHD in Patient 10 (R3), suggesting the temporal association of the clonotype with the 
onset of GVHD (Figure 4b).  However, Patient 10’s GVHD was not wholly resolved at R4, and 
polyclonality was restored at this time.  This suggests that if the clonal population at R3 was GVHD-
specific, it may have been one of a group of V families involved in GVHD pathogenesis in this 
patient, as there were no other clinically noted infections or complications at R3 with which to associate 
the clonal population.   
     Similarly for V23, oligoclonality was also detected at the time of GVHD in Patients 5, 9, 10, and 
11 (Figure 4c).  For Patients 5, 10, and 11, oligoclonal populations emerged at the time of GVHD in 
parallel with the increased expression of V23 at these times.  Neither Patient 10 nor 11 had complete 
resolution of GVHD at R4, and there was not a complete restoration of polyclonality at these times, 
further suggesting the potential role of these clonal populations in mediating GVHD.  In Patient 9, an 
increased expression of V23 started to emerge prior to GVHD (R2) and continually increased at the 
time of GVHD (R3) and at one-year post-HSCT (R4), with monoclonality at all times.  Interestingly, 
Patient 9’s GVHD was clinically resolved at R4, suggesting that this clonotype may not have been 
involved in GVHD as it’s highest expression was seen after disease occurrence was no longer clinically 
noted, or that the emergence of another clone was detected over that of the GVHD-associated clone.  It 
is also possible that this clonal population could have been involved in GVT effect since the increased 
expression persisted beyond temporal association with GVHD.  Since a continued increase in 
expression was not common beyond the clinical resolution of GVHD in our patients, this may be an 
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example of how to exclude certain clonal populations from their potential roles in the pathophysiology 
of GVHD.  Because qRT-PCR only amplifies CDR3 regions irrespective of VDJ rearrangements, we 
will use high throughput sequencing to determine the specificity of the T cell clones. With regards to 
Patient 11, the oligoclonality that was seen at the onset of GVHD (R2) persisted through one-year post-
HSCT (R4), and as GVHD was not clinically resolved at R4, the persistence of a GVHD-associated 
population was expected.  Though the qRT-PCR expression of V23 was lower at R4, the severity of 
the disease may have been minimal at this point.  Furthermore, Donor 11 also demonstrated 
oligoclonality, and the clonal populations seen in Patient 11 mirrored those of the donor, suggesting 
another possible explanation for the oligoclonality being that the clonotypes may be antigen-
experienced with clonality persisting due to delayed thymopoiesis.   
     For controls, we also performed spectratyping for patients who did not demonstrate increased 
expression relative to their donors in order to demonstrate that oligo- and mono-clonality was 
associated with antigen-driven T cell responses.  The controls used were:  Patient 9 for V4, Patient 11 
for V11, and Patient 6 for V23 (Figures 3, 4a-c).  Polyclonality is seen as a Gaussian distribution of 
CDR3 lengths, and is a result of the random insertion of nucleotides during VDJ rearrangement in T 
cell development.
62
  Though spectratyping of control samples was not always perfectly Gaussian (may 
have looked somewhat aberrant, particularly earlier-on after HSCT), there was still a distinction to be 
made based on sharp oligo- and mono-clonal peaks that were antigen-driven versus non-antigen-driven 
T cell populations.  Because thymopoiesis is delayed after HSCT, restoration of normal polyclonal T 
cell repertoires is often greatly delayed until naïve CD4
+
 subsets are restored.
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     From the cohort of GVHD patients, 5 out of 8 had GVHD defined as acute—Patients 5, 6, 9, 13, and 
14—with Patients 8, 10, and 11 having cGVHD.  Based on qRT-PCR and spectratyping data above for 
Vs 4, 11, and 23, we saw no difference in these V families being more representative of chronic or 
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acute GVHD, as clonally-driven T cell populations were identified in both GVHD types.  Patients 5 and 
13 had GVHD of the skin and gut, Patient 6 had delayed acute onset of the gut, and Patient 9 had acute 
onset for GVHD of the skin (chronic after day 100).  Patient 14 had aGVHD of the skin and late-onset 
acute grade IV gut GVHD.  Patients 8, 10, and 11 had cGVHD of the skin.  Patient 6 only demonstrated 
increased expression and oligoclonality of V4, suggesting that Vs 11 and 23 may be more specific to 
GVHD of the skin, as all other patients with increased expressions and oligoclonality for these V 
families had skin GVHD. 
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Figure 3: 
 
   
 
  
 
Figure 3.  qRT-PCR analysis demonstrates increased expression of TCR V families 4, 11, and 23 
in more than one patient with GVHD.  Peripheral T cells from recipients (R2-R5) were compared to 
their respective donors (D) at 90 days after HSCT (R2 for No GVHD group, and GVHD Patients 6, 8-
10), time of GVHD (R2 for Patients 5, 11, 13, 14; or R3 for Patients 6, 8-10), one-year post-HSCT (R3 
for No GVHD group, R4 for GVHD group except for Patients 10 and 13; R5 for Patients 10 and 13), or 
at time of relapse (R4 for Patient 10).  Expression of all TCR V families was normalized to CD3. 
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Figure 4: 
 
   
                       
 
 
Figure 4.  Spectratyping analysis of the CDR3 region of TCR V families with increased 
expression in more than one patient with GVHD.   a) Spectratyping analysis of V4 - Patients 5, 6, 8, 
10.  D and R are donor, and recipient, respectively, before HSCT.  R2 denotes 90 days post-HSCT for 
all patients except for Patients 5 and 11, for which R2 denotes time of GVHD.  R3 is time of GVHD 
(Patients 6, 8-10) or 90 days post-HSCT (Patient 11).  R4 is one-year post-HSCT, with the exception of 
Patient 10, for which R4 denotes time of relapse (10 months post-HSCT).  A control is also shown 
(based on low qRT-PCR expression) to demonstrate that increased expression corresponds to the mono- 
or oligoclonality that is seen at the time of GVHD.  ND: no data. 
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Figure 4b) Spectratyping analysis of V11 - Patients 5, 8-10.  D and R are donor, and recipient, 
respectively, before HSCT.  R2 denotes 90 days post-HSCT for all patients except for Patients 5 and 11, 
for which R2 denotes time of GVHD.  R3 is time of GVHD (Patients 6, 8-10) or 90 days post-HSCT 
(Patient 11).  R4 is one-year post-HSCT, with the exception of Patient 10, for which R4 denotes time of 
relapse (10 months post-HSCT).  A control is also shown (based on low qRT-PCR expression) to 
demonstrate that increased expression corresponds to the mono- or oligoclonality that is seen at the time 
of GVHD.  ND: no data. 
 
 Figure 4b: 
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Figure 4c) Spectratyping analysis of VPatients 9-11.  D and R are donor, and recipient, 
respectively, before HSCT.  R2 denotes 90 days post-HSCT for all patients except for Patients 5 and 11, 
for which R2 denotes time of GVHD.  R3 is time of GVHD (Patients 6, 8-10) or 90 days post-HSCT 
(Patient 11).  R4 is one-year post-HSCT, with the exception of Patient 10, for which R4 denotes time of 
relapse (10 months post-HSCT).  A control is also shown (based on low qRT-PCR expression) to 
demonstrate that increased expression corresponds to the mono- or oligoclonality that is seen at the time 
of GVHD.  ND: no data. 
 
 
 
 
 
Figure 4c: 
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TCR V families 9, 16, and 20 are commonly associated with GVT response in GVHD-free patients. 
     Since GVT effects are predominantly recognized as T-cell-mediated processes in which donor T 
cells recognize genetic disparities within recipients, we wanted to see if V families of increased 
expression in patients without GVHD were antigen-driven, and subsequently potentially involved in  
GVT responses.  As shown in Figure 5, TCR V9 was associated with an increased expression in all 
four patients without GVHD (3, 4, 7, and 12).  Correspondingly, oligoclonality was seen in Patients 3, 
4, and 7, at three months (R2) and one year (R3) post-HSCT for Patients 3 and 4, and at one year post-
HSCT for Patient 7 (Figure 6a).  (Due to sample limitations, there is no spectratyping analysis for 
Patient 12.) Patient 6 was used as a control for V9 (Figures 5, 6a), which showed oligoclonality at R2, 
though this was not at the time of GVHD and polyclonality emerged in subsequent timepoints, 
suggesting that the increased expression and clonality seen at R2 may be associated with either 
homeostatic proliferation of a limited T cell population or reactivity with residual disease.  Patient 8 is 
also shown as a control for low expression of V9, but this patient demonstrated monoclonality from 
R-R4, which was expected as a result of the continued immunosuppressive treatments this patient was 
receiving (this trend was also seen for Vs 2, 3, 7, and 17 in this patient).   
     TCR V16 showed increased expression in Patients 3 and 4 (Figure 5) and oligoclonality at three 
months (R2) and one year (R3) post-HSCT in both patients (Figure 6b).  Patients 7 and 9 were used as 
controls from the GVHD-free and GVHD groups, respectively.  Though Patient 7 demonstrated low 
expression of V16 relative to the donor, oligoclonality was seen at three months (R2) and one year 
(R3) post-HSCT, suggestive of the delayed thymopoiesis that is common in older patients, as there 
were minor clonal populations in addition to the major clonotype, and since an antigen-driven response 
should have shown an increased expression in qRT-PCR (Figures 5, 6b).  Patient 9 demonstrated more 
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polyclonal expression, which was expected as a control (Figure 6b), and though the clonality was not a 
―perfect‖ Gaussian distribution, it was still reasonably so considering that complete return of normal T 
cell repertoires is delayed by the slower rate of the re-establishment of thymopoiesis after HSCT. 
     TCR V20 expression was increased in Patients 3, 4, and 12 at three months (R2) and one year (R3) 
post-HSCT (Figure 5).  Patient 3 demonstrated oligoclonality at three months and one year post-HSCT, 
and Patient 4 demonstrated monoclonality at one year post-HSCT (Figure 6c).  The polyclonality that 
was seen at three months in Patient 4 was likely due to homeostatic proliferation, as there was an 
increased expression of V20 at this time.  Patients 7 and 10 were used as controls for V20, from the 
GVHD-free and GVHD groups, respectively.  As shown in Figure 6c, V20 was not detected in Patient 
7 at time R just prior to transplant, which was not surprising as evidenced by the extremely low qRT-
PCR expression (Figure 5).  Polyclonality was seen at three months post-HSCT (R2) in Patient 7, as 
expected by low expression.  Oligoclonality was seen in Patient 7 at one year post-HSCT (R3), and 
though the qRT-PCR expression was lower than that of the donor, this clonality could have been due to 
an antigen-driven response that happened some time prior to R3.  Such instances in which 
oligoclonality is detected without a corresponding increased expression demonstrate the limitations of 
qRT-PCR in amplying CDR3 regions without being able to distinguish between different VDJ 
rearrangements.  For the other control, Patient 10 demonstrated a skewed repertoire at R2 (Figure 6c), 
but this could be due to delayed thymopoiesis as the patient was still under immunosuppression.  Also, 
there was an increased expression in Patient 10 at R3 (Figure 5), though it could have been due to 
homeostatic proliferation as the T cell population at R3 was polyclonal.   
     Moreover, with regards to the GVHD-free patients, Patients 4 and 7 had mismatches of the DQB1 
allele:  Patient 4 (0201)/Donor 4 (02GM); Patient 7 (0302)/Donor 7 (0301) (Table 1).  It is possible that 
GVT-responses were alloreactive against these mismatches, though the increased expression and 
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oligoclonality of Vs 9, 16, and 20 were not exclusively seen in these two patients.  Patient 3 was 
homozygous for the DQB1 0602 allele, which Donor 3 also had, though Donor 3 also had a DQB1 
0503 allele.  However, because the patient does not express the 0503 allele, it would be considered a 
mismatch in a host-versus-graft response and not in a GVT response since the donor expresses the 
DQB1 0602 allele as well.
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Figure 5: 
 
 
 
 
Figure 5.  qRT-PCR analysis demonstrates increased expression in TCR V families 9, 16, and 20 
in more than one patient without GVHD.  Peripheral T cells from recipients (R2-R5) are compared to 
their respective donors (D), as previously described, with expression of all TCR V families normalized 
to CD3. 
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Figure 6.  Spectratyping analysis of the CDR3 region of TCR V families with increased 
expression in more than one patient without GVHD.   a) Spectratyping analysis of V9 - Patients 3, 
4, and 7 show monoclonality at the times of increased qRT-PCR expression (at R2 and R3 for Patients 3 
and 4, and at R3 for Patient 7); Patient 6 is shown as a control (low qRT-PCR expression).  D and R are 
donor, and recipient, respectively, before HSCT.  R2 denotes 90 days post-HSCT.  R3 is one year post-
HSCT in Patients 3, 4, and 7, and R3 also denotes the time of GVHD in controls 6, 9, and 10. R4 is one-
year post-HSCT for Patients 6 and 9, and ten months post-HSCT for Patient 10.  ND:  no data. 
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Figure 6b.  Spectratyping analysis of V16 - Patients 3 and 4 demonstrate monoclonality at the time of 
increased expression (R2 and R3).  Patients 7 and 9 are shown as controls of patients without and with 
GVHD, respectively.  D and R are donor, and recipient, respectively, before HSCT.  R2 denotes 90 days 
post-HSCT.  R3 is one year post-HSCT in Patients 3, 4, and 7, and R3 also denotes the time of GVHD 
in controls 6, 9, and 10. R4 is one-year post-HSCT for Patients 6 and 9, and ten months post-HSCT for 
Patient 10.  ND:  no data. 
Figure 6b:  
     
        ND 
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Figure 6c. Spectratyping analysis of V20 - Patient 3 shows oligoclonality at R2 and R3, and Patient 4 
shows monoclonality at R3.  Patients 7 and 10 are controls, without and with GVHD, respectively.  D 
and R are donor, and recipient, respectively, before HSCT.  R2 denotes 90 days post-HSCT.  R3 is one 
year post-HSCT in Patients 3, 4, and 7, and R3 also denotes the time of GVHD in controls 6, 9, and 10. 
R4 is one-year post-HSCT for Patients 6 and 9, and ten months post-HSCT for Patient 10.  ND:  no data. 
 
 
 
 
 
 
Figure 6c:  
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TCR V families 5 and 24 are privately associated with GVT response in Patient 3. 
     TCR V families 5 and 24 demonstrated increased expression in Patient 3, suggesting a potential role 
in a GVT response in this patient.  As shown in Figures 7a and 7b, there was an increased expression 
and a skewed clonal population of V5 in Patient 3 at one year post-HSCT (R3).  The spectratyping at 
R3 mirrored that at three months post-HSCT (R2), yet R2 did not have a corresponding increased 
expression, which may have been due to delayed thymopoiesis.  The spectratyping at R3 may then have 
been due to an increased expression of the dominant clone (noted at 435bp in Figure 7b) with a 
corresponding reconstitution of the T cell repertoire.  Since R3 represents one year post-transplant, the 
increased expression was less likely due to homeostatic proliferation as this predominantly occurs 
during lymphopenia early-on after transplantation.  Regardless, caution should still be used with skewed 
populations like the one seen in Patient 3, because the distinction between oligoclonal antigen-driven 
responses and skewed repertoires is less clear than if there is a strong monoclonal peak with a greater 
increase in qRT-PCR expression (less than 1-fold increase in V5 at 3R3 if considering the lower end of 
the error bar).  Figure 7a also shows an increased expression of V5 in Patient 12, but conclusions as to 
what this expression might correspond to will be determined in future studies (for limitations previously 
addressed).  Patient 4 was used as a control for V5 and showed polyclonality as expected.   
     As shown in Figures 7c and 7d, Patient 3 also showed increased expression and oligoclonality in 
V24, though the dominant clones seen (at R2 and R3) in Figure 7d mirrored the major clonotype of 
Donor 3’s T cell population.  
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Figure 7: 
 
 
 
 
Figure 7.  TCR V families 5 and 24 are associated with GVT response in a patient-specific 
fashion.  a) qRT-PCR analysis shows an increased expression of V5 in GVHD-free Patients 3 and 
12.  b) Spectratyping analysis of V5 for Patient 3 corresponds to oligoclonality.  Patient 4 is shown 
as a control.  c) qRT-PCR analysis of V24 shows increased expression of V24 in Patient 3.  d) 
Spectratyping analysis of V24 shows monoclonality in Patient 3 at R2 and R3.  Patient 4 is shown 
as a control.  Time points are as previously described. 
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7d) 
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Increased expression of TCR V families 2, 3, 7, 8, 12, 15, and 17 are shared by both GVHD and 
GVHD-free patients. 
     In addition to identifying V families that were increased in either the GVHD or GVHD-free patient 
groups, we also wanted to see if certain V families were commonly associated with patients in both 
groups.  As shown in Figure 8, TCR V families 2, 3, 7, 8, 12, 15, and 17 show increased expression in 
multiple recipients, respective to their donors, in both the GVHD-free and GVHD groups.     
     TCR V2 was increased in all GVHD-free patients as well as in GVHD Patients 6, 9, 10, 11, and 13.  
As shown in Figure 9 with regards to V2, GVHD-free Patients 3 and 7 showed oligoclonality at one 
year post-HSCT (R3), as expected based on their respective qRT-PCR data.  The clonality in Patient 3 
followed a similar trend to that seen in this patient for V5 in which the same clonality was seen at R2 
and R3 though there was only a corresponding increased expression at R3.  Also, the oligoclonality was 
borderline skewed, again demonstrating the fine line between antigen-driven peaks and the typical 
aberrant restoration of normal T cell repertoires in patients following HSCT.  The clone seen at one 
year post-HSCT (R3) in Patient 7 mirrored that seen in the patient before transplant, which may 
represent continuation or reactivation of that antigen-experienced population, as Patient 7 had 63% 
recipient T cell chimerism at R3.  Patients 6, 10, and 11 all showed a major clone over a polyclonal 
background, demonstrating restoration of the V2 repertoire during homeostatic proliferation.  Because 
there was no retention of the oligoclonality from the time of GVHD onset (R2) at R3 in Patient 11, the 
skewed population at R2 could also be explained by homeostatic proliferation with delayed 
thymopoiesis since a GVHD-associated clone should have continued from R2 to R4, as GVHD was not 
wholly resolved at R4.  Though Patient 9 demonstrated increased expression at R3, there was a 
polyclonal population, suggesting that the increased expression was due to homeostatic proliferation.  
An oligoclonal population emerged at R4, though there was no corresponding increased expression, 
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demonstrating the limitations of qRT-PCR in being unable to determine the proportions of specific 
CDR3 sequences, as opposed to amplifying individual CDR3 sequences.  Patients 4 and 8 were run as 
controls for V2.  Patient 4 demonstrated polyclonality, as expected.  Patient 8 demonstrated 
oligoclonality from R2-R4, which as aforementioned was common, as this patient was still being 
treated with immunosuppressive therapies that hindered reconstitution of a normal T cell repertoire. 
     For TCR V3, GVHD-free Patients 3, 7, and 12 and GVHD Patients 6, 11, and 13 showed increased 
expression (Figure 8).  Patient 3 demonstrated oligoclonality at three months (R2) and one year (R3) 
post-HSCT (Figure 10) with minor clones in addition to the major clone, representing an oligoclonal 
expansion over a polyclonal background.  Patient 7 demonstrated oligoclonality only at R2, which may 
be due to the mixed chimerism (52% recipient T cells), as this clone mirrored that of the patient at time 
R prior to HSCT (Figure 10).  Though there was also increased expression at one year post-HSCT (R3) 
in Patient 7 (Figure 8), the clone mirroring that from R2 was less dominant as the spectratyping was 
more polyclonal (Figure 9), which may be explained by homeostatic proliferation and initial re-
establishment of thymopoiesis.  Retention of the clone from R2 at R3, along with the emergence of 
other clones at R3, may also demonstrate mixed chimerism showing a major clone from either the 
patient or donor and a polyclonal population from the other (Patient 7 had 63% recipient T cell 
chimerism at R3).  With regards to the GVHD patients, oligoclonality was seen in Patients 6 and 11 at 
their respective times of GVHD (Figure 10).  Because Patient 6 was still being treated for GVHD at one 
year post-HSCT (R4), the continuance of the clonal population from the time of GVHD onset (R3) at 
R4 was expected.  Patient 11 showed oligoclonality of three dominant clones at R2 and R3, as expected 
based on increased expression (Figures 8, 10), and though the onset of GVHD is at R2, the patient was 
still being treated for GVHD at R3 and R4, so the continued clonality was expected.  Furthermore, that 
there are potentially three antigen-associated clonal populations in Patient 11, it is possible that they 
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were related to GVHD and/or GVT.  Patients 4, 8, and 9 are shown in Figure 8 as controls.  Patients 4 
and 9 demonstrated polyclonality, as expected.  Patient 8 showed oligoclonality, which, as 
aforementioned, was resultant of continued GVHD treatment, thus hindering the reconstitution of a 
diverse T cell repertoire.    
     Increased expression of TCR V7 was seen in GVHD-free Patient 3 and in GVHD Patients 6, 9, 10, 
11, 13, and 14 (Figure 8).  As shown in Figure 11, Patient 3 showed oligoclonality at R2 and R3, 
suggesting that the increased expression may have been due to an antigen-driven response.  Patients 4 
and 7 are shown as controls.  Though a skewed repertoire was seen at R2 in Patient 4, it may have been 
due to delayed thymopoiesis.  Patient 7 showed a dominant clone at R2, which mirrored that of the pre-
transplant clone seen at R, suggesting retention of that clonal population from the patient as there was 
52% recipient T cell chimerism at R2.  Because this clone was still the major clone seen over the 
polyclonal population at R3, this clone may again represent the patient’s mixed chimerism, with the 
dominant clone being from either the donor or recipient and a polyclonal population being due to the 
other.  Patient 6 demonstrated polyclonality at the time of GVHD onset (R3), which was likely a result 
of homeostatic proliferation.  Furthermore, Patient 6 demonstrated oligoclonality at R2 and R4, though 
there were not corresponding increases in expression at these times.  This suggests that these clonal 
populations may have been involved in GVT responses at either time.  Patients 9, 10, and 11 all showed 
oligoclonality corresponding to their increased expressions of V7 (Figure 11).  The clonality seen at 
the time of GVHD onset in Patients 10 (R3) and 11 (R2) continued at R3 and R4, which was not 
unexpected, as neither patient had complete resolution of GVHD at R4.  Patient 8 was used as a control 
from the GVHD group and again demonstrated oligoclonality as a result of immunosuppression.  The 
donors for Patients 10 and 11 had somewhat skewed T cell populations for V7 at the time of 
transplant, which may be representative of antigen-experienced T cell populations.  Patients 9, 10, and 
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11, as well as Patients 3, 7, and 8, all demonstrated oligoclonality at time R prior to transplant.  This 
may indicate that the V7 family is associated with common viral or pathogen immunity, as a skewed 
repertoire was also seen in Donors 7, 10, and 11.  Furthermore, the V7 family may have a more 
restricted repertoire based solely on base pair size, as the skewed repertoires were seen throughout the 
spectratyping data for V7 both in patients with and without increased expression.  This is also implied 
in the broader bases of the peaks, which shows a saturation of clones within a given base pair region, 
unlike the Gaussian distribution seen in polyclonal populations with major peaks separated by 3 
nucleotides.   
     The TCR V8 family was increased in GVHD-free Patients 4 and 12 and GVHD Patients 5, 10, 11, 
and 14 (Figure 8).  As shown in Figure 12, Patient 4 showed oligoclonality at times R2 and R3, 
indicative of an antigen-driven response.  Donor 4 also showed a dominant peak around the same base 
pair size as that seen at R2 and R3 in the recipient, indicating that this clone may have been antigen-
experienced.  If this donor clone was represented in the clonal population demonstrated at R2 and R3, it 
may demonstrate the ability for antigen-experienced T cells to recognize non-self peptide:MHC 
complexes.
63
  The human memory T cell population is dominated by reactivities to common DNA 
viruses (i.e. – CMV, EBV, HSV), and the possibility of cross-reactivity of antigen-experienced T cells 
with foreign peptide:MHC complex is high, despite the rarity of individual cross-reactivities.
63
  As 
shown by Melenhorst et al., antigen-experienced CD4
+
 and CD8
+
 T cell subsets are able to recognize 
MHC-mismatched APCs.
63
  Since Patient 4 had an HLA-DQB1 mismatch (Table 1), this clonally-
driven population may have been involved in a GVT response through either cross-reactivity of an 
antigen-experienced T cell or from direct HLA-dependent recognition.  Patient 3 is shown as a GVHD-
free control, and though there was slight oligoclonality at R2, it was likely due to the patient still being 
under immunosuppressive treatment at R2, as the repertoire became more polyclonal at R3.  GVHD 
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Patients 5, 10 and 11 showed oligoclonality, as expected by increased expression (Figures 8, 12).  
Patient 10 showed a dominant clonotype over a skewed background at the time of GVHD onset (R3).  
This clonal population was also seen at R2 and R4, indicating the potential for a GVHD-associated 
clone to be detected prior to clinical diagnosis, and the continuance of the clone at R4 was expected as 
this patient’s GVHD was not wholly resolved at R4.  Patient 11 demonstrated dramatic clonality that 
mirrored that of Donor 11.  Though Patient 11 did not have any HLA mismatches, these clonotypes 
were likely antigen-experienced, and may have been involved in a GVT or GVHD response against 
non-self peptide:MHC in a peptide-dependent manner.  Patient 6 showed a slight increase in expression 
at R2, but the aberrant clonality fits with homeostatic proliferation as opposed to an antigen-driven 
response.  Patient 8 is shown as a control from the GVHD group, and was predominantly polyclonal as 
expected.   
     As shown in Figure 8, expression of the TCR V12 family was increased in GVHD-free Patients 4 
and 12 and GVHD Patients 6, 8, 10, and 13.  Patient 4 showed a somewhat oligoclonal population at R2 
(Figure 13), but this was likely due to delayed thymopoiesis and homeostatic proliferation, as 
polyclonality was completely restored at R3.  Patients 6, 8, and 10 all demonstrated oligoclonality at the 
time of GVHD as expected based on increased qRT-PCR expression (Figures 8, 12).  However, GVHD 
was not clinically resolved at R4, and clonality only persisted in Patient 6 at R4, indicative of 
continuance of a GVHD-associated clone.  Furthermore, the major clonal populations seen in Patients 6 
and 10 were the same size (433bp; Figure 12), suggesting a role for a GVT effect to a mHAg that is 
restricted to the hematopoietic system.  Patients 3 and 11 were used as controls, and both demonstrated 
polyclonality as expected. 
    Continuing through Figure 8, expression of TCR V15 was increased in GVHD-free Patients 3, 4, 
and 12 and GVHD Patients 10, 11 and 13.  Figure 14 shows oligoclonality in Patient 3 at R2 and R3, 
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indicating an antigen-driven response, and Patient 4 was predominantly polyclonal, indicating 
homeostatic proliferation.  Patients 10 and 11 also demonstrated oligoclonality at the time of GVHD, as 
expected.  The continuance of clonality from R2 through R4 in Patient 10 may depict the ability to 
detect a GVHD-associated clone prior to clinical diagnosis (R3), and since GVHD was not wholly 
resolved at R4, this better supports the possibility of this clonal population being associated with 
GVHD.  The sharp monoclonality seen in Patient 11 mirrored the clonotypes seen in both donor and 
recipient before transplant, suggesting that this population may have been antigen-experienced to a 
common virus or pathogen.  If this clonal population was antigen-experienced, it may have been able to 
cross-react with non-self peptide:MHC complexes in a peptide-dependent manner (as there are no HLA 
mismatches in Patient 11).  Patient 7 is shown as a GVHD-free control and depicted oligoclonality, 
which may have been due to both mixed T cell chimerism and retention of the recipient’s clonotype 
from R (as discussed previously for this patient) and delayed thymopoiesis.  Patient 8 is shown as a 
control from the GVHD group, and though there was slight oligoclonality at R2, it was consistent with 
delayed thymopoiesis as polyclonality was more evident at R3 and R4. 
     For the last TCR V family shared by both GVHD-free and GVHD patients in Figure 8, expression 
of V17 was increased in GVHD-free Patients 3 and 12 and GVHD Patients 10, 11, and 13.  Patient 3 
showed oligoclonality at R3 (Figure 15), as expected based on increased qRT-PCR expression.  
However, the clonality seen at R3 mirrored that seen at R2 when there was not a corresponding 
increase in expression, reiterating the caution in defining certain oligoclonal populations as either 
oligoclonally antigen-driven responses or as skewed repertoires resultant of delayed thymopoiesis and 
restoration of a normal T cell repertoire.  Patient 4 is shown as a control from the GVHD-free group 
and demonstrated polyclonality as expected.  Patients 10 and 11 demonstrated oligoclonality at their 
times of GVHD, R3 and R2, respectively.  The clonality demonstrated in Patient 10 persisted from R2-
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R4, suggesting the ability to potentially identify GVHD-associated T cell populations prior to clinical 
diagnosis, and as this patient’s GVHD was not completely resolved at R4, the continuance of this 
clonal population was expected.  The clonality seen at R2 and R3 in Patient 11 may have been involved 
in a GVHD or GVT response.  Since Patient 11’s GVHD was still being treated at R4, if the R2 and R3 
clonal populations were GVHD-associated, they should have persisted at R4, though they may have 
been less prominent if the GVHD was very minimal at that time.  Patient 8 is shown as a control from 
the GVHD group and demonstrated the same monoclonal trend that was evident in previous V 
families, as this patient was under continued immunosuppression.  There was also no clonal population 
detected in the V17 family for Patient 8 at time R prior to transplant, and as the qRT-PCR expression 
was very low at this time, this result was not surprising. 
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Figure 8: 
 
                   
 
Figure 8.  TCR V families with increased expression in patients with and without GVHD.   qRT- 
PCR analysis of TCR V families 2, 3, 7, 8, 12, 15 and 17 in all patients.  Times points are as 
previously described. 
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Figure 9: 
 
 
 
 
 
Figure 9.  Spectratyping analysis of TCR V2 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V2 expression (R3).  
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 6, 10; 
and, R2 for Patient 11).  Patients 4 and 8 are negative controls based on low qRT-PCR expression of 
V2.  Time points are as previously described.  ND:  no data. 
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Figure 10: 
 
 
 
 
 
Figure 10.  Spectratyping analysis of TCR V3 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V3 expression (R2 -R3).  
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 6, R2 for 
Patient 11).  Patients 4, 8, and 9 are controls.  Time points are as previously described.   ND:  no data. 
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Figure 11:  
 
 
 
 
Figure 11.  Spectratyping analysis of TCR V7 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V7 expression (R2 -R3).  
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 9, 10; 
and, R2 for Patient 11).  Patients 7 and 8 are controls.  Time points are as previously described.  ND:  no 
data. 
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Figure 12: 
 
   
 
 
Figure 12.  Spectratyping analysis of TCR V8 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V8 expression (R2 -R3).  
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patient 10; and, 
R2 for Patients 5 and 11).  Patients 3 and 8 are controls.  Time points are as previously described.  ND:  
no data. 
 
 59 
 
Figure 13: 
 
 
 
 
Figure 13.  Spectratyping analysis of TCR V12 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V12 expression (R2 -
R3).  Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 6, 
8, and 10).  Patients 3 and 11 are controls.  Time points are as previously described.  ND:  no data. 
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Figure 14: 
 
 
 
 
Figure 14.  Spectratyping analysis of TCR V15 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V15 expression (R2 -
R3).  Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patient 10, 
R2 for Patient 11).  Patients 7 and 8 are controls.  Time points are as previously described.  ND:  no 
data. 
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Figure 15: 
 
 
 
 
Figure 15.  Spectratyping analysis of TCR V17 in patients with and without GVHD.  Blue boxes 
denote oligoclonality in patients without GVHD at the time of increased TCR V17 expression (R3).  
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patient 10, R2 for 
Patient 11).  Patients 4 and 8 are controls.  Time points are as previously described.  ND:  no data. 
 
     
      ND 
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DNA extraction from GVHD-biopsy tissues identified specific V families at the site of GVHD. 
     We next wanted to determine if there was a direct correlation between the levels of T cell clones in 
the circulation with those at the site of GVHD.  GVHD Patients 5, 6, 8, and 11 had available paraffin-
embedded biopsy samples from which we were able to extract DNA.  We used GAPDH primers to run 
PCR reaction to confirm the extraction of DNA from these samples.  Figure 14 shows the results of 
these PCR reactions for GAPDH, with all products showing bands on a 1% agarose gel around the 
300bp region.  Patients 5, 6, and 11 had one sample, corresponding to the time of GVHD, which was R2 
for Patients 5 and 11, and R3 for Patient 6.  Patient 8 had two samples, Sample A corresponding to the 
first clinical indications of GVHD onset (R3), and Sample B, corresponding to three months after 
Sample A, during active chronic GVHD.  We also used a control sample from non-GVHD Patient 4 who 
had a biopsy taken around 4 months post-HSCT, which was classified as folliculitis (an infection in the 
hair follicles, often caused by bacteria).  Based on qRT-PCR and spectratyping, we ran PCR using 
primers for those TCR V families that demonstrated both increased expression and oligoclonality in 
order to see if we could detect these V families at the site of GVHD.  We also ran negative control 
PCR reactions based on V families that had low qRT-PCR expression.   
     Patient 5 demonstrated increased expression and oligoclonality in V families 4, 8, 11, and 23 
(Figures 3, 4, 8, 12).  PCR products for Vs 4, 11, and 23 were detected at the site of GVHD, as shown 
by the PCR product bands on a 1% agarose gel (Figure 17).  Control reaction for Vwas detected at 
the site of GVHD, though there was polyclonality at this time in the peripheral T cells (Figures 17a,b).  
For Patient 6, PCR reactions were run for Vs 2, 3, 4, and 12 because they demonstrated both increased 
expression and oligoclonality (Figures 3, 4, 8, 10, 13).  From these reactions, Vs 2 and 4 were detected 
at the site of GVHD (Figure 18).  Vs 6 and 9 were run as negative controls and did not show bands on 
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the agarose gel, as expected (Figures 5, 6a, 21a,b).  
    For Patient 8, because Sample A corresponds to R3 and Sample B is from 3 months after R3 and 
therefore does not have a corresponding peripheral T cell sample, we ran PCR products for Sample B 
based on our predictions for Sample A.  Patient 8 demonstrated increased expression and oligoclonality 
in V families 2, 3, 4, 11, 12, 17 (Figures 3, 4, 8-10, 13, 15).  From these, Vs 2 and 4 were detected in 
both Samples A and B, and V11 was detected in Sample B.  V9 was run as a negative control based 
on low qRT-PCR expression (Figures 5), though it was detected at the correct size (539bp), and a 
smaller second band was detected around the 400bp region (Figure 19) (the second band could be due to 
primers binding to homologous sequences in the DNA or to amplification of non-transcribed DNA with 
stop codons).  Though Patient 8 demonstrated oligoclonality for V9 at all times (R-R4), this could have 
been a result of his continued immunosuppression, as the oligoclonality was seen in multiple V 
families of low expression throughout his course of treatment.  Furthermore, V9 may merely represent 
non-clonal T cell populations at the site of GVHD.  Since the clonality of the V families detected at the 
site of GVHD is not known from our data, we cannot eliminate the various possibilities for these T cells. 
     For Patient 11, PCR was run for those V families of both increased expression and oligoclonality:  
2, 3, 7, 8, 11, 17, and 23 (Figures 3, 4, 8-12, 15).  V6 was also run due to its increased expression in the 
peripheral blood (Figure 21a).  As shown in Figure 20, Vs 2, 3, 6, 15 and 17 were detected at the site of 
GVHD.  V11 was run as a negative control, and correspondingly no band was detected. 
     It has been shown that Vs 2 and 6 are common in the healthy skin of adults, so though these V 
families may have low expression in the peripheral blood, they may also be common in the skin.
64
  We 
detected V2 at the site of disease in each of our samples that were from skin GVHD (Patients 8 and 
11), in which Patient 11 had increased expression and a skewed repertoire (Figure 8, 9), and Patient 8 
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demonstrated low expression (Figure 8) and oligoclonality (Figure 9) in the peripheral blood.  Low 
expression with corresponding oligoclonality was expected for Patient 8, as continued 
immunosuppressive treatments hindered the re-establishment of a normal T cell repertoire.  With regards 
to V6, it was only detected at the site of GVHD in Patient 11, and though there was a slight increase in 
qRT-PCR expression in the peripheral blood, polyclonality was seen at this time (Figure 21a,b).  To 
compare our results to those of Menssen et al. in which Vs 2 and 6 were detected in the skin of normal 
healthy adults,
64
 we ran PCR reactions for the control folliculitis sample, Patient 4, in which V2 was 
identified, but not V6 (Figure 22).  There was both low expression (Figures 8, 21a) and polyclonality 
(Figures 9, 21b) of V2 and 6 in Patient 4, demonstrating that these V families were not actively 
involved in antigen-driven responses in the peripheral blood.  However, since V2 was identified in the 
folliculitis sample from Patient 4, our results suggest that V2 may have been involved in pathogenesis 
of folliculitis.  This further suggests that V2 may be commonly found in the skin, where it is activated 
by local inflammation and/or infections, as it was found in each of our skin GVHD samples as well as 
our non-GVHD control.  Furthermore, V2 was detected at the site of gut GVHD in Patient 6, in which 
there was an increased expression and skewed repertoire (Figures 8,9), and in Patient 5 who 
demonstrated low expression and polyclonality (Figures 8, 17b) in the blood.  As evidenced in Patients 5 
and 6, even if V2 is commonly found in the skin, it may be commonly associated with the T-cell-
mediated inflammatory response in GVHD, regardless of the tissue involved.   
     Overall, V4 was identified in three, V11 was identified in two, and V23 was identified in one, out 
of the four patients with GVHD biopsies.  Patients 5 and 6 had acute GVHD of the gut, whereas Patients 
8 and 11 have chronic GVHD of the skin.  There was no unique correlation of Vfamilies between 
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patients with chronic versus acute, or gut versus skin, GVHD.   
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Figure 16: 
 
 
 
 
 
Figure 16.   Extraction of DNA confirmed by GAPDH control.  DNA was extraction from paraffin-
embedded biopsy samples from the site of GVHD, at the time of GVHD.  PCR was run with GAPDH 
primers as a control to verify extraction of DNA.  Patients 5, 6, and 11 have one sample, corresponding 
to the time of GVHD, which is R2 for patients 5 and 11, and R3 for Patient 6.  Patient 8’s Sample A 
corresponds to the first clinical indications of GVHD onset (R3) and Sample B corresponds to three 
months after R3, during active chronic GVHD.  A control sample was also used from non-GVHD 
Patient 4 who had a biopsy about 4 months post-HSCT, which was classified as folliculitis. 
 
 
 
 
 
 
 
 67 
 
 
Figure 17: 
 
       
 
 
            
 
Figure 17.   Patient 5 DNA extraction.  a) PCR products yielded positive results for TCR Vs 4, 11, 
and 23 (indicated in bold) which showed increased qRT-PCR expression and oligoclonality.  Control 
sample V2 (underlined) was also detected at the site of GVHD, even though there was low expression 
and polyclonality in the peripheral blood at this time.  Expected sizes of products are shown in each well 
corresponding to the respective V families.  Results are shown on a 1% agarose gel. b) Spectratyping 
of V2 in Patient 5’s peripheral blood sample shows polyclonality at the time of GVHD (R2).  ND:  no 
data. 
17a) 
17b) 
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Figure 18: 
 
 
  
 
 
Figure 18.   Patient 6 DNA extraction.  PCR products yielded positive results for TCR Vs 4 and 2 
(indicated in bold), which showed high qRT-PCR expression and oligoclonality.  Control sample Vs 6 
and 9 were negative (italicized), as expected based on low qRT-PCR expression at the time of GVHD.  
Expected sizes of products are shown in each well corresponding to the respective V families.  Results 
are shown on a 1% agarose gel.   
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Figure 19: 
 
 
 
 
 
Figure 19.   Patient 8 DNA extraction.  The letters A and B correspond to time point R3 and three 
months after R3, both are times of GVHD.   There is no corresponding peripheral T-cell sample for the 
B sample, so the PCR reactions were chosen for both A and B sample based on qRT-PCR and 
spectratyping analyses at the time of R3.  PCR products yielded positive results for TCR Vs 2 and 4 for 
both A and B and V11 for B (indicated in bold).  Control reactions for V9 gave positive results for 
both samples A and B (underlined).  Expected sizes of products are shown in each well corresponding to 
the respective V families.  Results are shown on a 1% agarose gel. 
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Figure 20: 
 
 
 
 
 
 
 
Figure 20.   Patient 11 DNA extraction.  PCR products yielded positive results for TCR Vs 3, 17, 15, 
2, and 6 (indicated in bold).  V11 was run as a negative control (italics).  Expected sizes of products are 
shown in each well corresponding to the respective V families.  Results are shown on a 1% agarose 
gel. 
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Figure 21: 
 
 
 
 
 
 
 
 
Figure 21.  qRT-PCR and spectratyping analysis of V6.  a) qRT-PCR.  b) Spectratyping. The red 
box denotes the time in which V6 was detected at the site of GVHD in Patient 11.  ND:  No data.                       
 
 
21a) 
21b) 
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Figure 22: 
 
 
 
Figure 22.   DNA extraction from control sample for Vs 2 and 6.  V2 yielded positive results 
(underlined) and V6 was negative.  Results are shown on a 1% agarose gel.  
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Patient 10 – Relapse followed by remission and re-onset of GVHD post-DLI treatments 
     Patient 10 is a unique example of TCR V repertoire at onset of GVHD, resolvement of GVHD, 
relapse, and post-DLI remission and GVHD.  The course of her clinical events in which we obtained 
peripheral blood samples were: 3 months post-HSCT (R2), GVHD-onset 6 months post-HSCT (R3), 
relapse 10 months post-HSCT (R4), clinical resolvement of GVHD at one year post-HSCT (R5), 
remission and re-onset of GVHD (R6), and DLI treatments one month prior to R5 or two months prior 
to R6.  DLI is used to induce remission in patients who have relapsed, demonstrating the powerful GVT 
effects of donor allorecognition of malignant cells in recipients.
16,27,65,66
  Furthermore, use of DLI also 
carries a risk for post-DLI GVHD,
16,27,65,66
 as evidenced in Patient 10.    
     We looked at qRT-PCR and spectratyping data in Patient 10 in order to identify T cell clones that 
coincided with relapse (disappearance of GVT-associated clones) and post-DLI remission and GVHD 
(emergence of clones).  We first looked at V families that were commonly associated with GVHD—4, 
11, and 23 (Figures 23, 24a).  V4 demonstrated less than 1-fold increase in expression at R2, R3, and 
R5, with the same oligoclonality persisting from R2-R4, as previously mentioned, that was likely 
associated with cGVHD  that may have been detectable prior to clinical diagnosis at R3.  After the first 
DLI treatment, a second major V4 clone emerged at R5, but was less prominent at R6, suggesting that 
it was not involved in GVT or GVHD as clones involved in either effect should have persisted or 
emerged at R6.  With regards to V11, the strong clonotype at the onset of GVHD (R3) was no longer 
evident at R4 suggesting that it may not have been GVHD-specific, as clinical resolution of GVHD was 
not identified until R5.  Since polyclonality was restored at time of relapse (R4), the disappearance of 
the clone from R3 may have been GVT-associated.  Also, a new clonotype emerged at R6, suggesting a 
role for this T cell population in either GVHD or GVT, as both remission and GVHD occurred post-
DLI.  However, there was low expression of V11 at R6, further suggesting that this clonotype may 
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have been site-specific and less detecable in the peripheral blood.  For V23, we saw a skewed 
repertoire that persisted from R2-R5 that slightly shifted in size at R6, indicating a change in antigen-
specificity.  Since Patient 10’s first course of cGVHD was clinically resolved at R5, it may be that the 
continued clonal population was below clinical detection of GVHD. 
     We next wanted to look at Vs from the group of V families that were increased in patients with 
and without GVHD (Figures 23, 24b).  For V2, there was an oligoclonal population over a polyclonal 
background from R2-R4, suggesting a role for a GVHD-specific clone.  At R5, this clone was no longer 
evident, suggesting a role in a GVHD response, as clinical resolution was around R5.  At R6, a new 
oligoclonal population emerged that may have had a role in either GVHD or GVT.  In V7, the peristent 
clone from R2-R5 was diminished at R6, at which time a new clone emerged.  This clone at R6 mirrored 
that of the one in the recipient prior to transplant, suggesting a role in anti-myeloma response.  In V8, 
the major clonotype that was seen from R2-R4 was no longer present at R5 or R6, suggesting that it may 
have been specific for the patient’s first bout of GVHD.  V12 showed a similar trend to that of V8.  
V15 showed a dominant clone that persisted from R2-R6, though a polyclonal background didn’t 
emerge until R5.  Since the skin was involved with both the first and second course of GVHD, it may be 
that this clone was GVHD-specific.  Also, V17 followed a similar trend to that seen in V15.   
     Lastly, we looked at Vs 9 and 20 from the group of Vs commonly associated with GVHD-free 
patients to see if there was a correlation with GVT response, as well as at V6 since there was also an 
increase in qRT-PCR expression for this V family (Figures 23, 24c,d).  With regards to V9, an 
oligoclonal population emerged over at polyclonal background at R4.  This clone wa not likely involved 
in a GVT response, since it was at the time of relapse (R4) and prior to DLI treatments (prior to and after 
R5), at which a GVT-specific clone should have disappeared by R4 or appeared after R5.  V20 
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demonstrated polyclonality from R3-R6, demonstrating that it was not involved in an antigen-driven 
response.  In V6, there was a skewed repertoire from R3-R5 that became more oligoclonal at R6, 
suggesting a clonally-driven response involved in either GVHD or GVT effects. 
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Figure 23: 
 
 
 
 
 
Figure 23.  Expression of V families in Patient 10.  D: donor sample at time of transplantation; R2: 
recipient sample 3 months post-transplant; R3: time of GVHD onset at 6 months post-HSCT; R4: time 
of relapse at 10 months post-HSCT; R5: 1-year post HSCT, one month after 1
st
 DLI treatment; R6: 22 
months post-HSCT, two months after 2
nd
 DLI treatment, time of remission and re-onset of chronic skin 
GVHD.  
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Figure 24 
 
 
 
 
 
 
 
 
 
Figure 24.  Spectratyping analysis for Patient 10.  a) Spectratyping of V families 4, 11, and 23 in 
Patient 10.  D: donor sample at time of transplantation; R2: recipient sample 3 months post-transplant; 
R3: time of GVHD onset at 6 months post-HSCT; R4: time of relapse at 10 months post-HSCT; R5: 1-
year post HSCT, one month after 1
st
 DLI treatment; R6: 22 months post-HSCT, two months after 2
nd
 
DLI treatment, time of remission and re-onset of chronic skin GVHD.   
24a) 
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Figure 24b) Spectratyping analysis of V families 2, 4, 7, 8, 12, 15, and 17 in Patient 10.   D: donor 
sample at time of transplantation; R2: recipient sample 3 months post-transplant; R3: time of GVHD 
onset at 6 months post-HSCT; R4: time of relapse at 10 months post-HSCT; R5: 1-year post HSCT, one 
month after 1
st
 DLI treatment; R6: 22 months post-HSCT, two months after 2
nd
 DLI treatment, time of 
remission and re-onset of chronic skin GVHD.   
 
Figure 24b: 
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Figures 24:  c) Spectratyping of V families 9 and 20in Patient 10;  d) Spectratyping of V6 in Patient 
10.   D: donor sample at time of transplantation; R2: recipient sample 3 months post-transplant; R3: time 
of GVHD onset at 6 months post-HSCT; R4: time of relapse at 10 months post-HSCT; R5: 1-year post 
HSCT, one month after 1
st
 DLI treatment; R6: 22 months post-HSCT, two months after 2
nd
 DLI 
treatment, time of remission and re-onset of chronic skin GVHD.   
Figure 24c: Figure 24d: 
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Discussion 
 
 
     Our identification of specific T cell clonotypes commonly associated with GVHD or GVT supports 
the dominant characterization of GVHD as a T-cell-mediated inflammatory disease and the role for T-
cell-mediated alloreactivity in both GVHD and GVT responses.
7,28,31
  Current treatment of GVHD, both 
prophylactic and established, consists of broad immunosuppression, which not only mediates GVHD, 
but also increases the risk for opportunistic infection and incidence of relapse secondary to decreased 
GVT responses.  The ability to identify T cell clones involved not only in GVHD but also in GVT would 
allow targeted depletion of GVHD-associated clones and augmentation of those involved in GVT 
responses.   
     By isolating RNA rather than DNA from peripheral T cells, our results are more representative of 
those TCR V that were transcribed to mRNA for protein translation.  Since oligoclonal and monoclonal 
CDR3 patterns are associated with strong immune responses, looking at mRNA expression by qRT-PCR 
and spectratyping of the CDR3 region allowed us to identify T cell clonotypes involved in antigen-
driven responses.
52
  By identifying V families that met both of these criteria, we were able to make 
temporal associations of T-cell-mediated responses at the time of GVHD, as well in association of GVT 
effects in the absence of any clinically noted infections.   
GVHD 
     Though we isolated RNA from un-separated T cells, several studies have noted the association of 
skewed, oligoclonal T cell populations with CD8
+
 subsets and polyclonal populations with CD4
+
 
subsets.
67,68
  In one such study characterizing T cell expansions in patients with myelodysplastic 
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syndromes (MDS), Fozza et al. observed that increased frequencies of expanded variable subfamilies 
in CD4
+
 and CD8
+
 T cells were mostly Gaussian, or skewed and oligoclonal, respectively, within the 
CDR3 regions.
67
  In the general characterizations of GVHD and GVT as T-cell-mediated responses, 
CD8
+
 CTLs damage cells bearing class I MHC, typically in the skin, gut, and liver in GVHD, and in 
myeloid or lymphoid tissues in GVT.
31,69
  Our spectratyping results coincide with these observations, as 
oligoclonality has been associated with the CD8
+
 subset.   
     Most studies characterize GVHD as a Th1- and Tc1-type cytokine mediated process, though this 
characterization is not absolute.  For example, though Th1- and Tc1-type cells are abundant sources of 
IFN-γ, which primes macrophages and monocytes for pro-inflammatory cytokine secretion, IFN-γ has 
also been shown to induce apoptosis in lymphocytes.
70
  Th1-type cytokines have been correlated with 
amplifying the development of aGVHD, whereas Th2 cells have been shown to reduce aGVHD.
10,41
  
Furthermore, though the alloreactive T-cell-mediated inflammatory response characterizes GVHD, this 
pathophysiology is broadly accepted with regards to aGVHD, as cGVHD is still less well understood.
3,17 
   
Since cGVHD is represented as more of an antigen-specific cellular and humoral immune response,
16
 
the role for CD4
+
 T cells is more plausible for chronic rather than acute GVHD.  It is also thought that 
antigenic spread and exposure may lead to the generation of autoreactive T cells, which have been 
implicated in the pathogenesis of cGVHD.
3,17,57
  Even if we accept the Th1- and Tc1- cytokine profiles 
as being restricted to aGVHD only, five out of eight GVHD patients had aGVHD.  As such, the 
argument for CD8
+
 CTL function is concrete for those five patients, yet entirely plausible for the three 
patients whose GVHD was defined as chronic, as their clonality profiles were similar to those with 
aGVHD.  Furthermore, though CD8
+
 subsets are the major cytotoxic effectors in GVHD, CD4
+
 T cells 
have been shown to have cytotoxic functions in a MHC class II restricted manner.
34,71
  Since our patients 
who developed GVHD did not have class I or II mismatches (with the exceptions of Patients 13 and 14 
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(Table 1)),  we can reasonably suggest that GVHD-specific CTL function is peptide-dependent in the 
context of mHAgs. 
     Furthermore, because the thymus and bone marrow environments are susceptible to damage by pre-
conditioning treatments, regeneration of lymphoid-derived T cells is limited after HSCT.
72
  Though de 
novo generation of T cells from progenitors occurs via thymopoiesis, peripheral expansions of residual 
mature T cells are also a major contributing pathway in T cell reconstitution.
62
  After HSCT while 
patients are lymphopenic, any remaining residual host T cells and the donor T cells transferred within 
the graft undergo homeostatic peripheral expansion (HPE).  These early HPEs are typically 
characterized by oligoclonal and skewed repertoires, as peripheral expansions of mature lymphocytes 
are driven by antigen stimulation and/or homeostatic cytokines.
62
  Under the premise that HPE augments 
the environment for alloreactive T cell clones, it may be possible to identify GVHD-associated clonal 
populations prior to clinical diagnosis, especially in instances in which GVHD onset is around the time 
of tapering or ending of prophylactic immunosuppression, as in our Patients 5, 6, 8, 9, and 10.  The 
onset of GVHD for Patients 11, 13, and 14 occurred while they were still on immunosuppression, 
showing the ability of HPE to augment expansion of alloreactive T cell clones, even if to a lesser degree, 
as immunosuppression does not abrogate the allorecognition itself.    
     It has been shown that HPE of CD8
+
 T cells is more efficient than HPE of CD4
+
 cells, resulting in 
reduced CD4
+
 T cell counts and inverted CD4/CD8 ratios for months to years following HSCT in hosts 
with limited thymic function.
62
  This supports the likelihood of GVHD-associated clones representing 
CD8
+
 T cells, as CD4
+
 T cell number and function highly depends upon thymic-dependent T cell 
regeneration, which only occurs in a small fraction of adults who undergo HSCT.
72
  Furthermore, there 
has been an association of Th2 cytokine subsets and Tregs with lower incidence/severity of aGVHD.
37,41
  
With delayed restoration of the CD4
+
 subset after HSCT, the ability to downregulate T cell proliferation 
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is greatly hindered,
36
 thus allowing the continued expansion of alloreactive T cell populations involved 
in the pathogenesis of GVHD.   
     Diverse T cell repertoires may not be restored until thymopoiesis is restored, and although the 
thymus is involuted after puberty, it is still capable of generating new T cells, albeit at a much slower 
rate.
73
  In adults, each successive decade reduces the incidence of re-establishment of thymopoiesis, thus 
reducing the level of naïve cells produced and exported into the peripheral blood.
74
  Over the age of 45 
(as in all of our patients at the time of HSCT except for one at age 44), the frequency of significant 
renewal of thymopoiesis is severely reduced and normal levels of naïve CD4
+
 T cells may not be 
reached until after 2 years.
74
  In many older adults, this recovery of a normal level may take 3-5 years, 
and in some, may remain below normal levels for decades [reviewed in Williams].
62
  Because of delayed 
thymopoiesis, we are not surprised to find that some patients who were used as controls for their low 
qRT-PCR expression of certain TCR V families demonstrated aberrant T cell repertoires, as a normal 
Gaussian distribution may take years to be re-established.  Furthermore, as Patient 8 was under 
immunosuppression throughout his course of treatment (R2-R4), it was not surprising to see 
oligoclonality in many V families that had low expression, as the reconstitution of his T cell repertoire 
was continually suppressed.  Similarly, early increases in expression of a V family showing an aberrant 
or skewed repertoire (at a non-disease time) followed by decreased expression and polyclonality may 
merely represent the typical T cell reconstitution seen in patients after HSCT—HPE driven by 
homeostatic cytokines during a time of insufficient thymopoiesis before restoration of diverse naïve 
CD4
+
 T cells (which are characterized by polyclonal Gaussian spectratyping of the CDR3 region).
62
 
     Without any other clinically noted infections or complications at the same times as those of our 
GVHD samples, we can reasonably propose that the clonotypes we identified may be the alloreactive 
agents of GVHD within these patients.  Our results (Vs 4, 11 and 23 in the GVHD group and Vs 2, 3, 
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7, 8, 12, 15, 17 in the ―shared‖ GVHD/GVT group) are consistent with previous studies that have shown 
that oligoclonal expansions of V families is common and often correlates with GVHD.53  In addition to 
identifying T cell clones in the circulation of patients with GVHD, we were also able to identify some of 
these V families at the site of GVHD.  Other studies have shown that overall T cell repertoires in skin 
lesions involved in GVHD differed from that in peripheral blood.
57,75,76
  We, however, were able to 
identify some V families that were increased in the peripheral blood in an antigen-driven manner 
(oligoclonality) that were also detectable at the site of skin and gut GVHD.  From those V families 
which we identified as being commonly associated with patients with GVHD (V4 –Patients 5, 6, 8, 10; 
V11 – Patients 5, 8, 9, 10, 13; V23 – Patients 5, 9, 10, 11, 13), we were able to identify all Vs at the 
site of GVHD in at least one patient:  V4 –Patients 5, 6, 8; V11 – Patients 5, 8; V23 – Patient 5.  
Aside from our GVHD-specific group of V families, some of the V families whose expression was 
increased and also demonstrated oligoclonality in the peripheral blood in patients both with and without 
GVHD (Vs 2, 3, 7, 8, 12, 15, 17) were detected at the site of GVHD:  V2 – Patients 6, 11; Vs 3, 15, 
17 – Patient 11.   
     Additionally, Liu et al. observed that GVHD-specific clones may be difficult to detect in peripheral 
blood as the degree of expansion away from the site of disease is variable.
53
  We noticed this for a few 
V families that were detected at the site of GVHD, though their expression was not increased in the 
peripheral blood:  V2 – Patients 5, 8; V9 – Patient 8; V23 – Patient 5.  For Patient 5, the expression 
of V2 was almost 9-fold lower than that of Donor 5, suggesting that this V family may in fact be 
detected at the site of GVHD, but not by its level of expression in the blood.  For Patient 8, both Vs 2 
and 9 were roughly 2-fold lower than that of the donor, again suggesting that some GVHD-associated 
clones may be detected at the site of disease but not in the peripheral blood.  For all other Vs detected 
 85 
 
at the site of GVHD, their respective expressions in the blood were at least 2-fold higher in the GVHD 
samples than in the donor samples.  On the other hand, V23 had less than 0.5-fold increased expression 
over Donor 5, suggesting that it may be difficult to establish a baseline fold-increase that can be used as 
a predictor of GVHD-specific clonotypes.  We did not note a difference in the ability to detect clones 
with regards to chronic or acute manifestation of GVHD, as we were able to identify at least half of the 
V families that were oligoclonally increased in the periphery at the site of GVHD in patients with both 
chronic (Patients 8, 11) and acute (Patients 5, 6) GVHD.   There was also no strong difference in those 
Vs that were detected in skin (Patients 8, 11) or gut (Patients 5, 6), as V2 was found in all patients and 
Vs 4 and 11 were detected in both gut and skin GVHD. Furthermore, we were able to compare our 
results with other groups that identified V families at the site of GVHD:  C. Liu et al. detected Vs 2, 
6, 17, and 23;
53
 Hirokawa, et al. identified V6;76 X. Liu et al. identified V2,77 and Beck et al. 
identified Vs 3 and 17,57 all in skin GVHD.   
     In addition to V families detected at the site of GVHD, certain V families have been detected in 
the skin of healthy adults, such as Vs 2, 3, 6, and 23,64,78 each of which we identified at the site of 
GVHD (V2 – Patients 5, 6, 8, 11; Vs 3, 6, 23 – Patient 11).  For V2, expression in the peripheral 
blood was lower than that of the donors in Patients 5 and 8, but higher than the donors for Patients 6 and 
11.  We also detected V2 in our control sample (folliculitis), though there was a lack of both increased 
expression and oligoclonality in the blood.  If future studies detect V2 at the site of disease without an 
increased expression or oligoclonality in the peripheral blood, then it may follow with observations 
made by Menssen et al. that V2 commonly resides in the skin.64  Furthermore, V6 was detected at the 
site of GVHD in Patient 11.  Though there was a roughly 2-fold increase in expression of V6 relative 
to Donor 11, the clonality was more suggestive of HPE than an antigen-driven response.  For Patient 11, 
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the two possibilities are that V6 may commonly reside in the skin or is detectable at the site of GVHD 
without increased expression or oligoclonality in the blood.  With future studies involving more patients, 
we will be able to see if there is an association of Vs 2 and 6 at the site of GVHD with either high or 
low expression in the blood.  Using more control samples will also help to identify V families that 
commonly reside in the skin or gut.  If skin-resident V families are involved in the pathogenesis of 
GVHD, then it suggests that conditioning regimen damage to host tissues causes activation of such T 
cells at the site of GVHD, whereas those V families not common in the skin of healthy individuals are 
recruited to the site of disease.   
     Though we isolated RNA from our peripheral blood samples, we isolated DNA from the GVHD-
biopsy samples.  Using DNA, those TCR V families identified at the site of GVHD were representative 
of one copy per rearranged TCR per cell.
57
  We expected to detect V families at the site of GVHD that 
were also detected in the peripheral blood.  Exceptions to this were seen in instances in which V 
families were detected at the site of GVHD without a corresponding increased expression in the blood, 
with either polyclonal (V2 – Patient 5) or oligoclonal (V9 – Patient 8) repertoires in the blood.  We 
plan to use high throughput sequencing in order to determine whether higher copies of certain VDJ 
recombination for a given TCR V may predict GVHD or GVT at a molecular level. 
      Furthermore, other studies have noted CD8
+
 T cell infiltrates at the site of GVHD,
20
 and the absence 
of CD8
+
 infiltrates in normal, healthy skin.
78
  Future spectratyping analysis of the T cell clones detected 
at the site of disease will help us determine which T cells are active in the disease (oligoclonal) and 
which are bystanders common to the disease tissue (polyclonal). 
 
 
 87 
 
GVT 
     Studies have shown a correlation with aGVHD and improved disease-free survival, and that patients 
with cGVHD from matched sibling donors correlate with fewer relapses (though also increased 
TRM).
17,25,79
  For these reasons, the question then remains as to whether the mechanisms and effectors 
for GVHD and GVT are fundamentally different.
53
  This question is especially prominent when we 
consider the augmentation of antigen-driven T cell responses early-on after transplantation when 
homeostatic cytokines promote T cell expansion, which primes the environment for both GVHD and 
GVT responses.  It has also been shown that GVT effects can occur in the absence of GVHD, which 
implies that certain mHAgs that are expressed by malignancies are not expressed on the non-
hematopoietic-restricted tissues that are targeted in GVHD.
9,15
  However, with clinical observations that 
associate GVT with GVHD, there may be an overlap of mHAg expression, though those mHAgs that 
are only expressed on hematopoietic cells have become the target of interest for their potential roles in 
augmenting GVT effects.
43
  Though our patients are heterogeneous with regards to disease, the 
potential to identify T cells involved in GVT effects is plausible in the context of mHAgs whose 
expression is limited to the hematopoietic system.   
     Within the group of GVHD-free patients (3, 4, 7, 12), Vs 9, 16, and 20 demonstrated both 
increased expression and oligoclonality, suggesting a GVT-role for these T cells.  Patient 3 also 
demonstrated increased expression and clonality in Vs 5 and 24, which implies that GVT-specific T 
cells recognize mHAgs that are unique to that individual.  Of the Vs we identified in either our 
GVHD-free or GVHD patients, a few other studies have associated some of these V families in the 
peripheral blood with various diseases:  Tan et al. noted oligoclonal expansions of Vs 3 and 15 in 
patients with diffuse large B-cell lymphoma (DLBL)
80
 and Tanaka-Harada et al. observed biased usage 
of Vs 9 and 15 in acute myeloid leukemia (AML), Vs 4 and 12 in myelodysplastic syndrome (MDS), 
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and Vs 5 and 20 in patients with AML and MDS (as well as in healthy donors),81 suggesting the 
ability to identify V families that recognize mHAg in a hematopoietic-restricted manner. 
     GVT responses are generally thought to involve T-cell-mediated cytotoxicity, with CD8
+
 subsets 
being the predominant CTLs.
82
  However, CD4
+
 subsets are also recognized as having cytolytic 
effector functions,
28, 34-36
 suggesting their potential role in cytotoxic-mediated GVT responses as well.  
With the exception of Patient 10, all of our patients were relapse-free, which broadens the possibility of 
GVT-associated T cells being identified in more than just those four patients who did not develop 
GVHD.  Furthermore, three of our patients had HLA-DQB1 mismatches (Patients 4, 7, 13).  Since class 
II genes are restricted to hematopoietic antigen presenting cells, these mismatches may promote a GVT 
effect in an mHAg-independent or mHAg:MHC-dependent manner.
9,25,44
   
     Lastly, Patient 10 allowed us to look for GVT-associated clones that disappear at the time of relapse.  
V11 was the only TCR family that met this criterion, suggesting a role for V11 in GVT, as opposed 
to GVHD, as GVHD was not clinically resolved at the time of relapse.  We also expected to see new 
oligoclonal populations emerge at R6, which was defined as post-DLI remission and GVHD.  New 
clones did emerge in Vs 2, 7, 11, and 23, suggesting potential roles for these Vs in either GVHD or 
GVT responses.  Patient 10’s remission after DLI treatments demonstrates the GVT effect in 
eradicating her disease.
32
  Since GVHD is also common after DLI treatments,
 16,27,65,66
 the specificity of 
these clones will help distinguish which clones may be involved in which process.  
Clinical Correlations  
     Overall, when we look at the patients in this study and consider major risk factors (HLA-mismatch, 
female donor to male recipient, PBSC vs. BM) that are associated with development of GVHD, we 
were able to make a few observations that will be better validated with a larger patient cohort in the 
future.  With regards to HLA-matching, a mismatch at any of the HLA- A, -B, -C, and –DRB1 alleles 
 89 
 
has been associated with worse overall survival (OS).
83
  All patients were 8/8 matches for these four 
HLA-alleles, with the exception of Patient 14, who had an HLA-B mismatch (Table 1).  Patient 14 
developed late-onset acute GVHD of both skin and the GI system, and also died six months after 
HSCT, showing a direct correlation with the increased risk factors associated with the HLA-B 
mismatch.   Also, Patient 14’s GVHD was likely due to HLA-disparity, since the prevalence of 
aGVHD is upwards of 60-80% in recipients of grafts with one HLA allele mismatch.
4   
Mismatches of 
the DQB1 allele have not been shown to have an impact on OS or increased incidence of GVHD.
83
  
Two of our three patients with an HLA-DQB1 mismatch were GVHD-free and are still alive over two 
years post-HSCT, and the one who developed aGVHD is still alive over one year post-HSCT.   
     Many studies have noted an increased risk of GVHD when a male recipient receives a graft from a 
female donor, due to H-Y antigens.
15,28,42
  Two patients, 9 and 14, were male recipients of female 
grafts, and both developed aGVHD.  Antibodies specific for H-Y mHAgs have been associated with 
cGVHD,
84
 whereas each of these two patients developed aGVHD and also demonstrated increased 
expression and oligoclonality in their T cell repertoires, supporting the role of alloreactive T cells in 
their GVHD responses.   
     Donor grafts from PBSC have been associated with a greater incidence of GVHD, though grafts 
from BM have been associated with increased risk of relapse.
85
  All of our patients received PBSC, 
with the exception of Patients 10 and 13.  Patient 10 was the only patient in our study to relapse, which 
resolved after DLI treatments.  Interestingly, after Patient 10 went into remission, she developed 
GVHD again, showing the role of donor lymphocytes in promoting GVT effects as well as augmenting 
GVHD.  A study by the CIBMTR showed that CD34
+
 cell doses from PBSC grafts greater than 6 x 
10
6
/kg were associated with decreased risk of relapse.
86
  The average CD34
+
 cell dose in our GVHD-
free group was 7.03 x 10
6
/kg, whereas in our GVHD group, it was 4.54 x 10
6
/kg (Table 3).  All of the 
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patients in the GVHD-free group had cell doses greater than 6 x 10
6
/kg, whereas only two patients in 
the GVHD-group did (Patients 8 and 9).  This suggests that higher CD34
+ 
cell doses help facilitate 
better reconstitution of the immune system, as pointed out in Ringdén et al. 2009,
69
 and thus increase 
GVT effects.  Furthermore, two of our patients received BM grafts, Patients 10 and 13, with cell doses 
of 3.43 and 1.9 x 10
6
/kg, respectively (Table 3).  Bone marrow grafts are associated with greater 
incidence of relapse, as opposed to PBSC grafts, which was evidenced by Patient 10’s relapse.85   
     Furthermore, the higher amount of CD3
+
 T cells in PBSC grafts is also associated with increased 
incidence of GVHD.
7
  Interestingly, Patient 11 had the highest CD3
+
 T cell dose (11.35 x 10
8
/kg) and 
developed GVHD faster than all other patients, though only by a few days (Tables 2 and 3).  However, 
Patient 13 had the lowest CD3
+
 dose (4.3 x 10
7
/kg,
 
from a BM graft) and also developed GVHD (Table 
3).  Overall, there was no significant correlation of cell dose with increased incidence of GVHD in this 
cohort of patients.  Furthermore, early donor T cell chimerisms are also associated with increased risk 
of GVHD, which was observed in our patients (Table 2).     
Conclusion 
       In summary, we were able to identify three groups of TCR V families that were associated with 
either GVHD or GVT effects, or were commonly associated with both GVHD and GVT.  Our findings 
suggest that GVHD-associated T cell clones can be identified at the time of GVHD and used for 
targeted therapy of GVHD by means of TCR V-specific antibodies or small molecules that can target 
the associated T cell clones.  For those V families that were common between GVHD and GVT 
groups, we need a larger number of patients to determine whether these V families may be associated 
with GVHD and/or GVT.  For those patients with GVHD, if the mHAg:MHC complexes are expressed 
on cells both in the hematopoietic system and at the site of GVHD, it may well be that the same T cell 
populations are involved in both GVHD and GVT responses.  Future molecular analysis may also 
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reveal that there are CDR3 sequences common across TCR V families, which would suggest that 
CTLs from various V families may be able to recognize the same antigen with different avidities.30 
     Though the majority of our patients do not have any HLA-mismatches, analysis of T cell subsets 
(CD8
+ 
versus CD4
+
) may help us correlate the HLA-DQB1 mismatches with CD4
+
 recognition, as well 
as better understand the cytokine profiles of both acute and chronic GVHD.  Regardless of CD8
+
 or 
CD4
+
 subset, we observed clonal expansions of TCR V families that are indicative of antigen-driven 
responses.  For oligoclonal populations that emerge before the time of clinical diagnosis of GVHD, we 
may be able to detect GVHD-associated clones before clinical manifestation of the disease, 
demonstrating a potential role for T cell clonality in prognostics.  On the other hand, clonal populations 
that emerge prior to clinical diagnosis of GVHD may be involved in GVT responses.  We need to 
determine the fine specificity of GVHD- and GVT-associated TCR Vs in order to develop targeted 
therapies.  In this regard, high-throughput sequencing will allow us to identify the specificity of these 
clonotypes based on their CDR3 sequences.   
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